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1 Introduction  
1.1 Brief history of vaccines 
Vaccination is one of the most effective tools for the prevention of infectious 
diseases. The basic paradigm of vaccine development established by Louis 
Pasteur at the end of the 19th century (i.e. isolation, inactivation and injection 
of the causative agent) constitutes the foundation of classical vaccinology and 
led vaccine development throughout the 20th century [1]. Conventional 
approaches on the basis of these empiric principles have provided vaccines 
from three major categories: inactivated microorganisms, live-modified agents 
and subunit vaccines (composed by purified portions of the infectious agent) 
[2]. Not all pathogens, however, can be grown in culture and some 
microorganisms may require specific, sometimes expensive, conditions for 
growth. Others limitations include the necessity of safety procedures for the 
pathogen manipulation, and the possibility of an insufficient killing or 
attenuation, that may result in the presence of virulent organisms in the final 
vaccine. Recombinant DNA technologies have been used for the design of 
second-generation vaccines, to obtain rationally attenuated strains or highly 
purified antigenic components. Examples include bacterial toxins detoxified by 
molecular engineering, such as the pertussis toxin [3]. This approach, 
however, even if more refined, could require years [4], and in some cases, the 
conventional empiric approach was just insufficient to find appropriate 
solutions for the development of universal vaccines (i.e. meningococcus B). 
Although the history of genomics research can be traced back to the 1970s, 
with the development of DNA sequencing technology, the late 1990s marked 
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the beginning of the so-called genomics era, with the first complete genome 
sequenced of the free-living organism Haemophilus influenzae in 1995 [5]. 
Since then, emerging technologies have allowed the sequencing of a genome 
to be completed very quickly and sequencing of entire genomes has become a 
commonly used practice in research [6]. The approach referred to as „reverse 
vaccinology‟ uses the genome sequences of viral, bacterial or parasitic 
pathogens of interest rather than the cells as starting material for the 
identification of novel antigens, whose activity should be subsequently 
confirmed by experimental biology [7]. In general, the aim is the identification 
of genes potentially encoding virulence factors (on the basis of sequence 
similarities to known pathogenic proteins) and secreted or surface-associated 
proteins (using several computational tools identifying the presence of amino 
acid motifs responsible for targeting the mature protein to the bacterial surface 
(signal peptides, anchoring motifs), to the lipid bilayer (lipoproteins), to the 
integral membrane (transmembrane domains) or for recognition and 
interaction with host structures). The selected ORF were expressed in a 
heterologous system, Escherichia coli, purified and tested as vaccine in an 
animal model of infection. When an antigen provides promising protection in 
animal model, it is further characterized before entering in clinical [8]. The first 
example of a successful application of the reverse vaccinology approach was 
the identification of vaccine candidates against Neisseria meningitidis 
serogroup B (MenB) that are now close to enter in the market. The success of 
reverse vaccinology for meningococcus has led to the application of this 
approach to a variety of other human pathogens, such as Streptococcus 
agalactiae, Streptococcus pneumoniae, Chlamydia pneumoniae, Bacillus 
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anthracis, Porphyromonas gingivalis, Mycobacterium tuberculosis, 
Helicobacter pylori and others [9], [10], [11], [12], [13], [14].  
In spite of the success of the reverse vaccinology, several aspects that could 
not be assessed by the approach are currently emerging. One of these 
aspects is the impossibility to obtain information about the post-translational 
modifications (PTMs) of the putative vaccine candidates. Moreover the 
necessity to use heterologous recombinant proteins may results in changes in 
the maturation, compared to the native proteins, which can affect their 
immunogenicity. Indeed, during the maturation the physico-chemical properties 
of a protein are rapidly and reversibly modified, influencing a number of cellular 
processes like:  
 oligomerization state 
 Interaction with other proteins or cofactors 
 change of enzyme activity by covalent or non-covalent “ group addition” 
 sub-cellular localization  
 half-life.  
Among these processes, the covalent modifications (PTMs) are reported to 
be of pivotal importance in eukaryotes. Indeed, cells of multicellular 
organisms are known for their extensive networks of PTMs in which different 
modification pathways converge in signal integration. By contrast, bacteria 
have often been erroneously considered as simple sacs of metabolites, 
optimized for fast growth and devoid of the regulatory network based on post-
translational modifications. Over the past years, this appears not to be the 
case, and it become fundamental to assess how these post-translational 
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modifications occurs, either at the pathogen level or in the host system during 
recombinant protein expression, and how they influence antigen 
immunogenicity and host recognition.  
 
1.2  Maturation of proteins 
The process of gene expression is not over when the genetic code has been 
used to create the sequence of amino acids that constitutes a protein. To be 
useful to the cell, this new polypeptide chain must fold up into its unique 
three-dimensional conformation, bind small-molecule cofactors required for 
its activity or assemble correctly with other protein subunits. These 
modifications are mainly achieved by the formation of non-covalent bonds. 
Moreover the folded proteins can also be covalently modified by protein 
kinases or other protein-modifying enzymes (Figure 1).  
 
Linear polypeptide molten globule Three-dimensional 
structure
Cofactor binding
Assembling with other 
proteins
Covalent modifications
P P
S S
 
Figure 1: scheme of the maturation of a protein 
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During or after its synthesis, different regions of the polypeptide starts to 
acquire their secondary structures leading to the formation of the molten 
globule, this is the first step of the maturation. Subsequently the structure of 
the protein, alone or with the help of molecular chaperones, became more 
compact with the formation of appropriate hydrogen bonds and van der 
Waals, ionic, and hydrophobic interactions. In this way the linear, or one-
dimensional, genetic message in the DNA is converted into the three-
dimensional structure of the protein [15]. For some proteins the attainment of 
the tertiary structure it‟s the last step of the maturation but many others do 
not reach their final biologically active conformation until they have been 
modified by one or more processing reactions. These modifications can be 
divided in two main groups based on the type of chemical bonds involved, 
non-covalent or covalent.  
 
Non-covalent modifications 
Non-covalent modifications mainly include binding of cofactors and the 
assembling with other protein subunits and are very similar between 
prokaryotes and eukaryotes. 
Cofactors binding: A cofactor is a non-protein chemical compound, organic or 
inorganic, that is bound to a protein and is required for the protein's biological 
activity. These proteins are commonly enzymes, and cofactors can be 
considered "helper molecules" that assist in biochemical transformations (e.g. 
alcohol dehydrogenase require the NAD cofactor). Cofactors can be divided 
into two broad groups: organic cofactors, such as flavin or coenzyme Q, and 
inorganic cofactors, such as the metal ions Mg2+, Cu2+, Mn2+, or iron-sulfur 
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clusters. Some cofactors are also covalently bound and are called prosthetic 
group (e.g. heme) [16]. 
Assembling with other subunits (quaternary structure of proteins): Many 
proteins have multiple polypeptide subunits (from two to hundreds). The 
association of polypeptide chains can serve a variety of functions. Many 
multi-subunit proteins have regulatory roles; the binding of small molecules 
may affect the interaction between subunits, causing large changes in the 
protein's activity in response to small changes in the concentration of 
substrate or regulatory molecules (e.g. the lactose repressor involved in the 
regulation of the lac operon in E. coli). In other cases separate subunits take 
on separate but related functions, such as catalysis and regulation, or serve 
primarily structural roles. A multi-subunit protein is also referred to as a 
multimer. A multimer with just a few subunits is called an oligomer. If a 
multimer has non-identical subunits, the overall structure of the protein can 
be asymmetric and quite complicated. However, most multimers have 
identical subunits or repeating groups of non-identical subunits, usually in 
symmetric arrangement [17].  
In the vaccine field it becomes fundamental to understand if a recombinant 
selected vaccine candidate will present epitopes similar to the native antigen 
that will be recognized by the host immune system at the moment of the 
infection. The growing evidences of the importance of conformational 
epitopes in the immune response [18] implicate that in order to develop 
efficacious vaccines, conformation and oligomerization state of selected 
antigens should be addressed. For this purpose the characterization of 
surface protein complexes and the evaluation of their relevance for the 
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immune response are essential. Epitopes rising from protein-protein 
interactions could not be induced by immunization with single or non 
correlated recombinant proteins. The works provided by the group of C.M. 
Ferreirós, on the characterization of neisserial PorA and PorB interactions 
show how the characterization of intact complexes is a crucial step in the 
search of potential vaccine candidates [19], [20] and [21]. Another example is 
the complex responsible for the endocytic entry of HCMV, composed by five 
proteins (gH, gL, UL128, UL130 and UL131). The work of McVoy and Gerna 
demonstrated that the majority of the neutralizing activity of convalescent 
human sera from HCMV-seropositive individuals targets the endocytic 
complex while sera from recipients of the gB vaccine (containing only the 
recombinant protein gB) showed an epithelial neutralizing titers that were, on 
average, 15-fold lower, indicating that the gH/gL/UL128/UL130/UL131 
complex is important during the infections and can be considered as a 
potential vaccine candidate [22]. 
 
Covalent modifications 
The covalent modifications or post-translational modifications (PTMs) are 
chemical modifications of a protein that occur after its translation. The post-
translational modifications of amino acids extend the range of functions of the 
protein by attaching it to other biochemical functional groups (such as 
acetate, phosphate, various lipids and carbohydrates), changing the chemical 
nature of an amino acid, or making structural changes (e.g. formation of 
disulfide bridges or isopeptide bonds). The role of covalent PTMs in bacteria 
just start to become of interest; their functions include stability, protection 
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from proteases and signal transduction. Potential modifications on bacterial 
proteins include proteolytic processing, phosphorylations, glycosylations, 
methylations and lipidations. Other modifications such as sulfations, 
hydroxylations and myristoylations do occur on proteins, but at this stage 
appear specific to eukaryotes [23].  
Proteolytic processing: Proteolytic processing is a major form of PTM which 
occurs when a protease cleaves one or more bonds in a target protein to 
modify its activity. This processing may lead to activation or inhibition of the 
protein's activity. Many cellular processes are triggered by proteolytic 
cleavage. The processing protease may remove a peptide segment from the 
C- or N-terminal extremity of the target protein (e.g. the activation of the 
trypsinogen by the enterokinase), but it may also cleave internal bonds in the 
protein that lead to major changes in the structure and function of the protein.  
An example of this last mechanism is the chemokine protease SpyCEP from 
Streptococcus pyogenes [24]. This protein is autocatalytically cleaved into 2 
fragments and the N-terminal prodomain remains structurally associated to 
the C-terminal portion and participate in the formation of the active site by 
providing one of the 3 residues of the catalytic triad. Another example of 
proteolytic processing of proteins is secretory proteins or proteins targeted 
specific cellular compartments (like the periplasm), which have their signal 
peptide removed by specific signal peptidases before or just after release to 
the extracellular environment or specific compartments [25]. 
Phosphorylations: Protein phosphorylation is a post-translational modification 
in which a serine, a threonine or a tyrosine residue is phosphorylated by a 
protein kinase by the addition of a covalently bound phosphate group. 
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Regulation of proteins by phosphorylation is one of the most common modes 
of regulation of protein function, and is often termed "phosphoregulation". In 
almost all cases of phosphoregulation, the protein switches between a 
phosphorylated and an unphosphorylated form, and one of these two is an 
active form, while the other one is inactive. The first clearly established 
example of phosphorylation of a bacterial protein was on the isocitrate 
dehydrogenase [26], in 1979, 25 years after the discovery of protein 
phosphorylation in eukaryotes. This enzyme was reported to be 
phosphorylated on a serine residue. In subsequent years, numerous other 
bacterial proteins phosphorylated on Ser, Thr or Tyr were discovered and the 
corresponding protein kinases and P-protein phosphatases were identified 
[27]. These protein modifications regulate all kinds of physiological 
processes. Ser/Thr/Tyr phosphorylation in bacteria therefore seems to play a 
similar important role as in eukaryotes. In addition to phosphate group, others 
related groups can be found attached to bacterial proteins. As example the 
PilE protein subunit of the Neisseria gonorrhoeae type IV pilus (Tfp) 
colonization factor can be uniquely modified by the covalent addition of  
different phospho-forms (i.e. phosphoethanolamine, phosphocholine and 
phosphoglycerol) to specific serine residues; has been proposed that these 
phospho-form modifications may influence pilus structure, function, and 
interactions with both the adaptive and innate immune systems [28].  
Glycosylations: Protein Glycosylation is the post-translational process by 
which saccharides are selectively added to specific protein residues utilizing 
two distinct mechanisms (N-linked or O-linked) in order to convey more 
structural stability or function to the native protein structure. Proteins are 
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glycosylated for several reasons; some glycoproteins are more stable once 
they have polysaccharides attached, others for cell recognition and 
communication, still some proteins are not able to fold properly without their 
accompanying glucidic chains. N-linked glycosylation is the most common 
form of glycosylation. It is widely employed by Eukaryotes and Archaea, but 
rarely in Prokaryotes. O-linked glycosylation is mainly found in Prokaryotes. 
The principal difference from between the N-linked and O-linked variants of 
protein glycosylation relies in the variety of the side-chain interactions, with 
type O- utilizing an oxygen based linker mechanism. Bacteria employ a wider 
variety of monosaccharides than Eukarya to glycosylate their proteins [29]. 
To date, protein glycosylation has not been related to bacterial signal 
transduction, but is recognized as an important pathogenicity determinant. In 
Pseudomonas aeruginosa, flagellin glycosylation plays a major role in 
virulence [30], and in Streptococcus parasanguinis and Streptococcus 
gordonii O-glycosylation of serine-rich adhesion proteins modulates the 
attachment to host cells [31]. 
Methylations: Methylation of proteins is the most common form of post-
translational modifications. As observed with other post-translational 
modifications, protein methylation is involved in the regulation of protein-
protein interactions resulting in a plethora of effects during key cellular 
events, including regulation of transcription, stress response, ageing and 
protein repair. Methylation on carboxylate side-chains covers up a negative 
charge and adds hydrophobicity. The carboxyl methylation mechanism is the 
memory component of the bacterial chemotaxis information processing 
system [32] that allows cells to respond to changes in attractant 
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concentrations rather than absolute levels (methylation and demethylation of 
the chemotaxis receptors allows the bacteria to measure the attractant 
concentrations). N-Methylation of lysines does not alter the cationic charge 
but increase hydrophobicity. In particular, dimethylation and trimethylation of 
lysine side-chains increase both hydrophobicity and steric bulk and can affect 
protein–protein interactions if they are in an interacting surface. 
Lipidations: The covalent binding of a lipid group to a peptide chain, also 
known as lipidation, can affect the activity of the protein and/or its cellular 
localization. Most bacterial lipoproteins are anchored to the plasma 
membrane by either di- (in case of Gram-positive bacteria) or triacylclycerol 
(in case of Gram-negative bacteria) linked to the side chain of an N-terminal 
cysteine via the sulfur atom, this modification is required for the cleavage of 
the signal peptide. Finally the mature N-terminal chain is further acylated on 
the amino group of the modified cysteine to obtain its final form [33]. Bacterial 
lipoproteins have been shown to perform various roles, including nutrient 
uptake, signal transduction, adhesion, conjugation, and sporulation, and to 
participate in antibiotic resistance, transport (such as ABC transporter 
systems) and extracytoplasmic folding of proteins. In the case of pathogens, 
lipoproteins have been shown to play a direct role in virulence-associated 
functions, such as colonization, invasion, evasion of host defense, and 
immunomodulation [34]. 
 
Unfortunately, few reports evidence how covalent PTMs could influence 
antigen immunogenicity and host recognition. For example the Apa 
deglycosylated antigen is less active than native molecules in eliciting 
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protective immune response against BCG in animal [35]. More recently, 
evidence suggesting that Pseudomonas glycosylated pili provide O-antigen-
specific protection via the mucosal and systemic routes of immunity have 
been reported [36]. Moreover, the work of the group of W. Zlotnick, on the 
characterization of the LP2086 protein from Neisseria meningitidis as vaccine 
candidate, shows that the lipidated version of the protein consistently elicited 
a greater immune response compared to the non-lipidated form [37]. 
The necessity of analytical methods, that allows studying the maturation 
steps of proteins in a fast and reliable way, becomes of pivotal importance in 
the vaccine research and the application of mass spectrometry is emerging 
as the method of choice in this field. 
 
1.3 Mass spectrometry 
Mass spectrometry is a highly reproducible methodology based on the 
determination of the molecular mass. This technique is based on the 
production of gas phase ions that are subjected to an electric field and can be 
resolved following their electro-dynamic attitude, which is dependent on their 
mass-to-charge ratios (m/z). 
Mass spectrometers can be divided into three fundamental parts, namely the 
ion source, the analyzer and the detector. Samples under investigation have 
to be introduced into the ion source of the instrument where the sample 
molecules are ionized. These ions are extracted into the analyzer region of 
the mass spectrometer where they are separated according to their mass-to-
charge ratios (m/z). The separated ions are detected and the generated 
signals sent to a data system where the m/z ratios are stored together with 
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their relative abundance for presentation in the format of an m/z spectrum. 
Mass spectrometers can be distinguished on the bases of their ionization 
system and on the type of analyzer, which is an essential component to 
define the accessible mass range, sensitivity and resolution. Between the 
different mass spectrometers available, the ones mainly used in this work are 
the MALDI/ToF and the ESI/Q-ToF.  The ionization methods used are “soft” 
ionization process like Matrix Assisted Laser Desorption Ionization (MALDI) 
and Electrospray Ionization (ESI) in which the biological sample is not 
destroyed during the ionization and the transfer to the gas phase. 
Matrix Assisted Laser Desorption Ionization (MALDI): MALDI is based on the 
bombardment of sample molecules with a laser light to induce sample 
ionization [38]. The sample is pre-mixed on a stainless steel plate with a 
highly absorbing matrix, i.e. a small aromatic molecule, that once excited is 
able to transfer energy and protons to the sample. Upon drying, the matrix 
molecules crystallize and solid sample/matrix co-crystals are finally formed. 
The MALDI-plate is then inserted into the ion source of the mass 
spectrometer under a high vacuum. A strong electrical field is applied 
between the plate and the extraction plate(s). A laser (generally a pulsed 
nitrogen laser at 337 nm) is fired onto the sample, resulting in a desorption 
event due to absorbance of the laser energy by the matrix molecules. Energy 
deposition into the matrix molecules leads to the conversion of the absorbed 
energy into heat. This rapid heating causes sublimation of the matrix crystals 
and subsequent expansion of matrix molecules and the co-crystallized 
analyte molecules into the gas phase. The ions are repelled from the target 
surface and accelerated into the mass analyzer (Figure 2). 
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Figure 2: MALDI source 
 
In positive ion mode the protonated molecular ions (M+H)+ are usually the 
dominant species, although they can be accompanied by salt adducts, and a 
trace of the doubly charged molecular ion at approximately half the m/z 
value. In negative ionization mode the deprotonated molecular ions (M-H)- 
are usually the most abundant species, accompanied by some salt adducts. 
Usually, MALDI is coupled to a time-of-flight (ToF) tube for mass analysis 
(Figure 3). The ToF tube is under a high vacuum (10-6-10-8 mbar) and is a 
field-free drift region. All ions enter the ToF tube at the same time and have a 
fixed kinetic energy, which is proportional to the applied voltage and the 
charge. This implicates the higher the mass of the ion, the lower its velocity 
and the longer it takes before the ion arrives to the detector. Based on their 
different velocities ions of different mass can be separated during their flight 
in the ToF-tube, measuring the time each ion takes to travel through the field 
free region. A detector amplifies and converts the signal triggered by the 
laser pulse and records the time-of-flight of the ions. Smaller ions fly faster 
16 
 
 
 
than larger ions, and their m/z ratio can be calculated from their flight time 
knowing the length of the tube and after calibration of the analyser using 
compounds with known masses. The length of the ToF is a crucial factor that 
affects both the resolution and the sensitivity of the mass spectrometer (the 
longer the tube, the higher the resolution but the lower the sensitivity).  
Inherent to the MALDI ionization process is a spread of kinetic energy of ions 
resulting in different points in time and space of ion formation within the 
source. Thereby ions with the same mass obtain different kinetic energies 
and velocities during their extraction out of the ion source. This results in 
peak broadening of the ion signal at the detector. Thereby the mass 
resolution is limited. This peak broadening can be reduced by the use of an 
ion mirror (or reflectron) at the end of the linear flight tube and by delayed ion 
extraction out of the ion source. 
 
 
Figure 3: Scheme of a MALDI-TOF spectrometer 
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With delayed extraction (DE), an extraction voltage pulse is applied to the 
sample plate between 100 and 500 ns following the laser pulse. During this 
delay, ions are allowed to spread in the source and higher energy ions will 
move further away than lower energy ions with the same mass. The 
extraction voltage is now applied as a potential gradient over the ion source. 
This compensates for the distribution of initial kinetic energies, so that ions 
with identical m/z values will be grouped in space before leaving the source. 
The ions will be then accelerated before the entrance of the ToF to reach the 
same kinetic energy. 
The reflectron has an applied voltage higher than that of the accelerating 
voltage in the ion source, resulting in ions slowing down and reversion of their 
flight path to the second detector. Ions with lower kinetic energies do not 
penetrate the reflectron as deep and thus turn around faster, catching up with 
ions of slightly greater kinetic energies that penetrate the reflectron deeper. 
Thereby, the flight times of ions with identical m/z values, but different kinetic 
energy values will be corrected when the ions arrive to the detector. 
Moreover the presence of the reflectron mirror allows to increase the 
travelling path of the ions in the ToF region without physically change the 
length of the tube; in this way is possible to achieve higher resolution with 
relatively small ToF devices.   
Electrospray ionization: Electrospray Ionization (ESI) is one of the 
Atmospheric Pressure Ionization (API) techniques and is well suited for the 
analysis of polar molecules ranging from less then 100 Da to more than 
1,000,000 Da in molecular weight [39]. 
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Figure 4: Electrospray source 
 
During standard electrospray ionization samples are dissolved in a polar, 
volatile solvent and pumped through a narrow, stainless steel capillary. A 
high voltage of 2 up to 5 kV is applied to the tip extremity of the capillary 
situated within the ionization source of the mass spectrometer and the 
sample emerging from the tip is dispersed into a spray of highly charged 
droplets, a process that is aided by a co-axially introduced nebulising gas 
flowing around the outside of the capillary. This gas, usually nitrogen, helps 
to direct the spray emerging from the capillary tip towards the mass 
spectrometer (Figure 4). The charged droplets diminish in size by solvent 
evaporation, assisted by a warm flow of nitrogen which passes across the 
front of the ionization source or by the heating of the capillary, and undergo to 
a fission event giving birth to smaller droplets (coulombic explosions). After 
different fission events the electric field on the surface of the droplets become 
large enough to allow the desorption of sample ions (Iribarne and Thomson 
model or Ion Evaporation Model, IEM), some of which pass trough a 
sampling cone or orifice into an intermediate vacuum region, and from there 
through a small orifice into the analyser of the mass spectrometer, which is 
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held under high vacuum. When the droplet contains very large molecules, 
like proteins for example, the molecules will not desorb, but are freed by 
evaporation of the solvent (Dole model or Charge Residue Model, CRM). 
This seems to occur when the molecular weight of the compounds exceeds 
5000 to 10000 Da [40].  
Electrospray is known as a “soft” ionization method as the sample is ionized 
by the addition or removal of a proton, with very little extra energy remaining 
to cause fragmentation of the sample ions. The peculiar aspect of this 
technique is the fact that it gives rise to multiply charged molecular-related 
ions such as (M+nH)n+ in positive ionization mode and (M-nH)n- in negative 
ionization mode. 
ESI source is generally coupled with quadrupole analyzers. A quadrupole 
mass analyser consists of four parallel rods that have fixed DC and 
alternating RF potentials applied to them. Ions produced in the source of the 
instrument are then focused and passed along the middle of the quadrupole. 
Their motion will depend on the electric fields so that only ions of a particular 
m/z will be in resonance and thus pass through to the detector. All other ions 
do not have a stable trajectory through the quadrupole mass analyzer and 
will collide with the quadrupole rods, never reaching the detector. The 
amplitude of the RF potential is modulated to bring ions of different m/z to be 
focused and thus transmitted to the detector to build up a mass spectrum 
(Figure 5). 
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Figure 5: The quadrupole analyzer 
 
Tandem mass spectrometry (MS/MS): Tandem mass spectrometry is used to 
obtain structural information about a compound by selecting and fragmenting 
specific ions inside the mass spectrometer and identifying the generated 
fragment ions. Tandem mass spectrometry also enables specific compounds 
to be detected in complex mixtures on account of their specific and 
characteristic fragmentation patterns. The fragmentation behaviour of a 
peptide is well understood and follows specific rules [41]; applying a low 
energy (i.e. below 100 eV) there are three different types of bonds that can 
fragment along the amino acid backbone: the NH-CH, CH-CO, and CO-NH 
bonds. Each bond breakage gives rise to two species, a charged one, that is 
monitored by the mass spectrometer and a neutral one; the charge can be 
retained on one of the two fragments depending on the chemistry and the 
relative proton affinity of the two species. Hence there are six possible 
fragment ions for each amino acid residue and these are labelled as in the 
Figure 6, with the a, b, and c ions having the charge retained on the N-
terminal fragment, and the x, y and z ions having the charge on the C-
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terminal fragment. The most common cleavage sites are at the CO-NH bonds 
which give rise to the b and/or the y ions. 
 
Figure 6: Scheme of peptide fragmentation  
 
Generally in a tandem mass spectrometer the two analyzers are separated 
by a collision cell filled with an inert gas (e.g. argon, xenon). When 
performing a classical MS analysis the collisions of the ions with the gas 
decrease their kinetic energy and stabilize their trajectories (cooling effect). In 
MS/MS experiments the ions are accelerated before the entrance of the 
collision cell where they collide with the gas and bring out their fragmentation. 
An example of such an instrument is the Quadrupole Time-of-Flight (Q-Tof), 
where the two resolving mass analyzers are separated by a fragmentation 
cell (Figure 7) [42]. 
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Figure 7: Scheme of an ESI/Q-ToF instrument 
 
Native mass spectrometry: Cellular processes are not typically performed by 
a single protein but by higher order protein oligomers. Therefore rather than 
focusing on individual proteins, it became more and more important to 
develop structural biology approaches capable of investigating intact 
functional protein complexes [40]. Native MS is a powerful technology that 
allows the topology of intact protein complexes to be investigated with high 
dynamic ranges [43]. Compared to the common approaches used for 
structural research such as X-ray crystallography, nuclear magnetic 
resonance spectroscopy or cryo-electron microscopy, native MS only 
requires low sample concentrations which permit the analysis of protein 
complexes close to their physiological conditions. In addition, this technique 
can be applied to study the interactions between proteins and small ligands 
and to measure the binding affinity of the complexes in the gas phase. For 
native MS the sample has to be diluted in an aqueous solution containing a 
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volatile buffer compatible with MS (i.e., ammonium acetate). A nanoESI 
source is generally used. NanoESI is a development of ESI for spraying very 
low amounts of very low concentration samples (nmol/mL). The technique 
has an increased tolerance to high aqueous solvents and salt contamination. 
Spectra can be obtained from pg of material with very little clean up being 
required. This increased performance is the result of lowering the inner 
diameter of the spray needle and reducing potentials normally used in ESI. In 
this type of source the analyte is sprayed from a tip with an opening of less 
then 5 m, smaller than the one used in standard ESI (130 m), thus 
producing smaller droplets which require a low amount of sample and “softer” 
conditions, compared to ES, to generate ions in the gas phase (e.g. 
temperature and pressure) (Figure 8). Standard nanospray uses disposable 
tips, but has problems with signal reproducibility between tips.  
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Figure 8: Comparison between denatured (on the top) e native (on the bottom) MS  
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Moreover the mass of intact proteins or protein complex is relatively high and 
the surface area exposed that can be charged is rather low, due to the 
retainment of the folded structure (Figure 8), hence the main type of analyzer 
used in native MS is the ToF, which theoretically does not have a limit in 
mass range. To obtain additional information from a native MS analysis, like 
the stoichiometry of hetero-oligomeric proteins or protein-ligand complexes, 
the spatial arrangement of the individual building blocks, and the stability of 
the complex, is necessary to use a hybrid mass spectrometer that allows the 
fragmentation of the analyzed sample. The Q-ToF mass spectrometer is well 
suited for this type of analysis coupling the capability to select ions of the 
quadrupole analyzer with the unrestricted mass range of the ToF. The main 
drawback of this type of instrument is the dynamic range of the quadrupole; 
up to now, the reduction of the RF frequency (around 300 kHz) allows to 
design quadrupole with a mass limit of 32 kDa, but it is not possible, for the 
moment, to use frequencies below 300 kHz for stability reasons [42].    
 
1.4 Aim of the thesis 
The study of the maturation process that occurs to a protein is of pivotal 
importance for the understanding of its function. This is true also in the 
vaccine field but in this case is also important to evaluate if inappropriate 
protein conformation and maturation play roles in the impairment of the 
functional immunogenicity of protein vaccines.  
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Mass spectrometry (MS) is the method of choice for the study of the 
maturation process since each modification that occurs during the maturation 
will lead to a change in the mass of the entire protein. 
Therefore the aim of my thesis is the development of mass spectrometry-
based approaches to study the maturation of proteins and the application of 
these methods to proteic vaccine candidates.  
The thesis is divided in two main parts. In the first part, I focused my attention 
on the study of the maturation of different vaccine candidates using native 
mass spectrometry. The analyses in this case have been performed using 
recombinant proteins produced in E. coli. In the second part I applied 
different MS strategies for the identification of unknown PTMs on pathogenic 
bacteria surface proteins since modified surface proteins are now considered 
for vaccine candidate selection. 
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2 Results and discussion 
2.1 Investigation on the maturation of different vaccine 
candidates using native mass spectrometry 
Introduction 
Many proteins acquire their biological active conformations only when they 
become part of higher order oligomers or interact with cofactors. These 
interactions are generally mediated by non-covalent bonds (i.e. hydrogen 
bonds, electrostatic and hydrophobic interactions) that are not retained using 
classical MS approaches (i.e. denaturing conditions). Native MS is a 
technique that allows the structural investigation of protein complexes without 
“destroying” non-covalent interactions, giving in the same time informations 
about covalent modifications [43]. Even though native MS is not as resolutive 
as crystallography or NMR the sensitivity, speed, selectivity and theoretical 
unlimited mass range and accuracy of this approach allow us to access to 
structural information of huge protein complexes (up to 2.2 MDa) [44] using 
nearly physiological conditions and low quantities of material. Within this 
approach nano-electrospray ionization is the most popular technique to ionize 
protein/protein and protein/ligand complexes. It is a soft ionization method 
that preserves non-covalent bonds and thus allows the study of the 
oligomerization state and cofactor binding of the proteins of interest.  
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Assignment of the oligomerization states of proteic 
vaccine candidates 
Oligomeric proteins abound in nature. They are composed of multiple 
subunits, which may be identical (homo-oligomeric proteins) or different 
(hetero-oligomeric proteins). It has been calculated that the average 
oligomeric state of cellular proteins is tetrameric, and a recent survey 
suggests that 35% or more of the proteins in a cell are oligomeric. 
Nevertheless, the proportion of oligomeric protein structures deposited in the 
Protein Data Bank (http://www.pdb.org/pdb/home/home.do) is significantly 
lower [17]. The study of protein oligomerization may be critical to understand 
the protein‟s physiological functions and is therefore necessary to fully 
characterize proteic vaccine candidates. Moreover the native MS analysis 
can give also important information about the presence of covalent 
modifications. We applied the native MS to seven recombinant proteic 
vaccine candidates or proteins of interest for vaccine development, belonging 
to three pathogenic microorganisms (Table 1), in order to study the 
oligomerization state and have preliminary informations about the presence 
of other modifications. 
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Protein Function Microorganism
GNA1030 Unknown Neisseria meningitidis
GNA2091 Hemolysin (putative) Neisseria meningitidis
NadR Repressor of NadA Neisseria meningitidis
NadA Adhesin Neisseria meningitidis
fHbp Factor H binding Neisseria meningitidis
PSL1 Unknown Staphylococcus aureus
SAL1486 Backbone pilus subunit Streptococcus agalactiae
 
Table 1: List of the proteins analyzed by native MS  
 
All the proteins were expressed in E. coli and purified avoiding denaturing 
steps. The results of the native MS analysis are summarized in Table 2. 
Among the seven proteins tested, three were found monomeric (GNA2091, 
fHbp and SAL1486), two were dimeric (GNA1030 and NadR, as suggested in 
[45]) and one was trimeric (NadA, as suggested in [46]). Interestingly, two 
forms of PSL1 were identified: (i) a covalent dimer (through an inter-protein 
disulfide bridge), and (ii) a monomer with a mass increase of 765.6 Da 
compared to the theoretical mass of the monomer. These two species were 
also present in the mass spectrum acquired in denaturing conditions. In 
addition, as observed with PSL1, the measured molecular weight of 
GNA1030 (only in native MS) and SAL1486 (also in denatured MS) differs 
from the expected one (by + 1457 Da and – 51 Da, respectively). Finally 
some degradation products were also observed in the NadA sample (at the 
N-terminal part) but the degradation does not seem to affect its 
oligomerization state (trimeric). 
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Protein Oligomerization Expected 
MW (Da)
Observed
MW (Da)
D Mass 
(Da)
GNA1030 Dimeric 37186.4 38643.2 +1457
GNA2091 Monomeric 20983.6 20983.9 /
NadR Dimeric 33728.6 33727.8 /
NadA Trimeric 103676.4 103676.6 /
fHbp Monomeric 27523.8 27523.8 /
PSL1
Dimeric (covalent) 54339.2 54340.2 /
Monomeric 27170.6 27936.2 +765.6
SAL1486 Monomeric 67426.1 67375.2 -51
 
Table 2: Oligomerization state and mass differences observed for the analyzed proteins  
 
Further analyses have been conducted to characterize the modifications 
found in the PSL1, GNA1030 and SAL1486 samples. 
 
Characterization of the mass increase found on PSL1  
PSL1 (Putative Staphylococcal Lipoprotein 1) is a Staphylococcus aureus 
lipoprotein with unknown function that is able to confer protection in mice 
immunization models [Bagnoli F., personal comunication]. Staphylococcus 
aureus is a Gram-positive opportunistic pathogen that can cause a spectrum 
of infections in humans and animals that differ in severity. Some relatively 
minor skin infections, such as folliculitis, impetigo and cellulitis, can progress 
to life threatening diseases like sepsis, endocardatis, osteomylitis and 
pneumonia [47]. Bacterial lipoproteins have been shown to perform various 
roles, including nutrient uptake, signal transduction, adhesion, conjugation, 
and sporulation, and to participate in antibiotic resistance, transport (such as 
ABC transporter systems) and extracytoplasmic folding of proteins. In the 
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case of pathogens, lipoproteins have been shown to play a direct role in 
virulence-associated functions, such as colonization, invasion, evasion of 
host defense, and immunomodulation, and have been described as 
promising vaccine candidates both in Gram negative [48] and gram positive 
bacteria [49]. Lipoproteins are initially translated as preprolipoproteins, which 
possess a N-terminal signal peptide of around 20 amino acids with typical 
characteristic features of the signal peptides of secreted proteins. 
Lipoproteins are either di- (in case of Gram-positive bacteria) or triacylated (in 
case of Gram-negative bacteria) on a highly conserved cysteine present at 
the C region of the signal peptide, in a region referred to as lipobox 
(Leu/Val/Ile-Ala/Ser/Thr/Val/Ile-Gly/Ala/Ser-Cys). By the consecutive action of 
the three enzymes pre-prolipoprotein diacyl glyceryl transferase (Lgt), 
prolipoprotein signal peptidase (LspA) and apolipoprotein N-acyltransferase 
(Lnt), lipoproteins are post-translationally modified after translocation over the 
cytoplasmic membrane. Lgt attaches a diacylglyceryl residue to the 
universally conserved cysteine in the lipobox by thioether-linkage. Then LspA 
removes the lipoprotein signal peptide and leaves the cysteine of the lipobox 
as the new amino-terminal residue. Finally, Lnt attaches a third acyl chain to 
the amino group of the modified cysteine [29]. The recombinant PSL1 used 
for this study has been expressed with a truncated N-terminal lipobox 
composed by only two amino-acids (GC) in order to avoid the binding of the 
diacylglycerol moiety and thus the anchorage of PSL1 to the membrane. The 
entire mass analysis of the protein in denaturing condition (Figure 9, lower 
spectrum) revealed the presence of three species with a molecular weight of 
27170.3 Da, 54340.2 Da and 27936.2 Da, respectively. The first two species 
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showed a mass in agreement with the monomeric and dimeric (covalent 
dimer through a disulfide bridge) form of the PSL1 protein respectively. The 
third specie showed a mass increase of 765.6 Da compared with the 
monomer, suggesting a covalent modification. In the entire mass spectrum 
performed in reducing conditions (Figure 9, upper spectrum) the only specie 
present is the monomer (27170.3 Da); these data confirms that the specie 
with a MW of 54340.2 Da in the unreduced spectrum is a covalent dimer 
through a disulfide bridge and reveal that the modification is also bound to 
the cysteine. Moreover, the presence of the modification only on the 
monomer further confirms this finding (in the dimer the cysteine residues are 
involved in the disulfide bridge formation, thus are not available for the 
modification). 
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Figure 9: Entire mass spectrum of PSL1 in denaturing conditions with and without reducing 
agent (upper and lower panel, respectively)  
 
In order to characterize the modification, the protein, with and without 
reducing agent, was analyzed by MALDI-ToF MS in negative ionization 
mode. As reported in Figure 10, a molecular ion at 766.6 m/z was only 
observed under reducing conditions. This peak can be assigned as the 
negative ion produced by the modification ([M-H]-); therefore the mass of the 
molecule bound to the protein is 767.6 Da.  
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Figure 10: Zoom in of MALDI-ToF spectrum of the PSL1 protein with and without reducing 
agent (upper and lower panel respectively). The peak at m/z 766.7 can be assigned as the 
negative ion of the modification [M-H]
-
 
 
It has already been reported in the literature that molecules with free thiols 
are able to link cysteine residues present in proteins through disulfide bonds 
(S-thiolation); this modification is generally observed in recombinant proteins 
secreted from E. coli cells [50]. S-thiolation in this case can be a response to 
environmental stress experienced by the cells or to the (patho)-physiological 
burden brought on by the expressed proteins. Various thiol modifiers have 
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been identified on recombinant proteins secreted from E. coli by MS including 
glutathione (mass increase of 305 Da), gluconoylated glutathione (mass 
increase of 483 Da), 4-phosphopantetheine (mass increase of 356 Da), 
dephosphorylated coenzyme A (mass increase of 685 Da) and coenzyme A 
(mass increase of 765 Da). Between the known thiol modifiers the coenzyme 
A presents a MW of 767.5 Da, which is in perfect agreement with the mass of 
the modification found on the PSL1 protein (767.6 Da). Based on these 
observations, it is possible to identify the molecule bound through a disulfide 
bridge to the PSL1 protein as the coenzyme A (CoA).  
The only cystein present in the protein is the one of the lipobox that in nature 
is covalently attached to a diacylglycerol moiety, thus both the formation of 
the covalent dimer and the binding of the CoA are not physiological 
modifications. 
The presence of the CoA covalently attached on the protein may be able to 
influence the immunogenicity of the protein in a positive mode since the 
structure of this molecule is similar to some Toll-like receptors (TLRs) 
agonists (e.g. Imiquimod and Resiquimod) (Figure 11) [51]. 
ImiquimodCoenzyne A Resiquimod
 
 
Figure 11: Structure of the coenzyme A and of two similar TLR agonists 
 
TLRs are pattern recognition receptors that can recognize pathogens via 
pathogen-specific molecular patters (PAMPs). TLRs play a crucial role in 
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both innate and adaptive immunity. Cells of the innate immune system can 
recognize invading pathogens as non-self through the TLRs leading to 
activation, maturation and induction of pro-inflammatory cytokines and other 
anti-microbial compounds. Immature dendritic cells (DCs) resident in 
peripheral tissues recognize these invading pathogens via numerous TLRs 
present on them. This leads to the activation, maturation and trafficking of the 
DCs to local lymph nodes and presentation of microbial antigens to naïve T 
cells leading to the induction of adaptive immunity against the invading 
pathogen. Furthermore, DCs can also regulate the T cell differentiation (Th1 
versus Th2) based on the pro-inflammatory cytokines that are produced by 
them which in turn may depend on the TLR:PAMP interaction. Since these 
molecules are able to boost the cell mediated immune responses and induce 
the formation of memory B cell, they can be used as vaccine adjuvants [52]. 
The ability of the modified PSL1, attached to the CoA, to activate the TLRs 
has been tested measuring the cytokines production of adherent 293T cells, 
stably expressing the indicated TLR, exposed both to the modified and 
unmodified protein. No differences has been found between the two samples 
(data not shown), indicating that the CoA does not possess an adjuvant 
activity. 
The effect of these modifications on the immunogenicity of the protein in vivo 
has not been tested, however to avoid any risk a mutated form of the protein, 
with the deletion of the cysteine residue, has been generated and named 
PSL1 Dcys. The mutated protein is still able to confer protection in mice 
immunization models and, after native MS analysis, showed a monomeric 
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oligomerization state and an observed MW in agreement with the expected 
one (data not shown). 
 
Characterization of the mass increase found on GNA1030  
GNA1030 is a periplasmic protein with unknown function present as an 
accessory antigen fused to the main antigen NHBA (GNA2132) in the 
4CMenB multicomponent vaccine against MenB developed by Novartis [8].  
N. meningitidis is an encapsulated Gram-negative bacterium that colonizes 
the upper respiratory tract of about 5-10% of humans. With a frequency of 
one to three cases per 100,000 of the population, the bacterium enters the 
bloodstream where it multiplies to high density and causes a form of sepsis 
characterized by the dramatic disruption of the endothelium and 
microvasculature. From the bloodstream the bacterium can cross the blood–
brain barrier and cause meningitis. The invasive infection is very dramatic, 
affecting mostly infants, children, and adolescents who do not have 
bactericidal antibodies raised against the infecting strain. Based on the 
chemical composition of the polysaccharide capsule, N. meningitidis strains 
can be classified into 13 different serogroups. Strains representative of five 
serogroups (A, B, C, Y, and W135) cause nearly all diseases in humans [52], 
[53]. Tetravalent vaccines composed of purified capsular polysaccharides of 
serogroups A, C, Y, and W135 have been available for three decades for use 
in adults, while conjugate vaccines, effective in all age groups, were 
developed a decade ago [54]. MenB differs from the A, C, Y, and W135 
serogroups because it is decorated by a capsular polysaccharide identical to 
the polysialic acid [α(2–8)N-acetylneuraminic acid] present in many human 
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glycoproteins. This mimicry rules out the use of polysaccharide–protein 
conjugate vaccines to combat MenB disease; therefore, there is currently no 
universal vaccine available against this bacterium. An alternative approach to 
vaccine development is based on surface-exposed proteins contained in 
outer membrane vesicles (OMVs). These vaccines have been shown both to 
elicit serum bactericidal antibody responses and to protect against 
developing meningococcal disease in clinical trials. However, the limitation of 
OMV vaccines is that the major protein antigens (i.e. PorA and PorB) display 
sequence and antigenic variability among the different MenB strains and, 
although they induce protective antibodies against the homologous strains, 
they fail to induce protection against heterologous strains [55]. To develop a 
universal vaccine against MenB, the genome of the bacterium has been 
sequenced [56] in order to discover novel putative antigens using the reverse 
vaccinology [7]. The antigens selected were prioritized based on their ability 
to induce broad protection as inferred by bactericidal assay (BCA) or 
observed in passive protection in the infant rat or mouse protection assays. 
The top antigens that met the prioritization criteria were: Neisseria heparin 
binding antigen (NHBA), factor H binding protein (fHbp), Neisseria adhesin A 
(NadA), GNA1030 and GNA2091 [8]. Among the selected antigens, 
GNA1030 is the only one with an unknown function. It is a member of the 
YceI-like family, a group of putative lipid binding proteins, showing 34% 
identity and 66% similarity with E. coli YceI. Only few structures of proteins 
belonging to this family are present in the Protein Data Bank [57], [58], [59]. 
These proteins share a common domain with an eight stranded beta-barrel 
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fold containing a lipid molecule (with the exception of the YceI-like protein 
from C. jejuni) (Figure 12).  
 
Protein Organism PDB code Ligand
YceI H. pylori 3HPE Erucamide
YceI-like E. coli 1Y0G 8PP
PI-binding protein T. thermophilus 1WUB Polyisoprenoid
X158 (YceI-like) S. degradans 2X32 Octaprenylpyrophosphate
X158 (YceI-like) S. degradans 2X34 Ubiquinone-8
YceI-like C. jejuni 2FGS No ligand observed
3HPE 1Y0G 1WUB 2X342X32 2FGS  
Figure 12: List of the proteins belonging to YceI-like family present in the PDB with the relative 
structures 
 
Therefore the mass increase found only during the native MS analysis of the 
GNA1030 protein (+ 1457 Da) could be due to the presence of a lipidic ligand 
non-covalently attached to the beta-barrel domain of GNA1030 (Figure 13, 
left inset). To demonstrate this hypothesis, an in source fragmentation 
experiment was performed during the native MS analysis of the protein. 
During electrospray ionization, ions entering through the sample cone are 
accelerated towards the extraction cone; the region between the sampling 
cone and the extraction cone is under a vacuum of 1-2 mbars (> 5 mbars 
during native MS experiments) (Figure 4). This pressure is relatively high 
owing to the presence of solvent vapor and nitrogen gas. In order to induce 
in-source fragmentation, the sampling cone voltage is increased, causing 
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ions entering the ion block to accelerate more quickly through the region 
(Figure 4); the resulting collisions can induce dissociation of the non-covalent 
complexes. After in source fragmentation, five different species are present 
with MW of 38642.6 Da, 37914.6 Da, 37186.3 Da, 19321.4 Da and 18593.3 
Da respectively (Figure 12). These species can be assigned as the dimer 
plus 1456 Da, the dimer plus 728 Da, the dimer alone, the monomer plus 728 
Da and the monomer alone. These data confirm the presence of a small 
ligand, with a MW of about 728 Da, non-covalently bound to the GNA1030 
protein with a 1:1 stoichiometry (Figure 13).  
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Figure 13: In source fragmentation of the GNA1030 protein (the native MS spectrum obtained 
before in source fragmentation is presented in the left inset) 
 
 
In order to fully characterize the ligand, the molecular ion released after in 
source fragmentation (m/z of 728.6 in positive mode (Figure 14) and m/z 
726.6 in negative mode), was selected  and fragmented, in both positive and 
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negative mode, in the collision cell of the mass spectrometer (MS/MS 
experiment). 
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Figure 14: Selection of the peak corresponding to the ligand after in source fragmentation of the 
protein in positive mode (a zoom in of the spectra showing the ion released is reported in the 
inset). 
 
In the negative MS/MS spectrum, the presence of two ions with -15 Da and -
30 Da compared to the parental ion, implies the neutral loss of one and two 
methyl group {([M-H]-)-CH3 and ([M-H]
-)-2CH3)} (Figure 14, A). Moreover, the 
presence of a repetition of seven ions with a delta mass of 68.1 Da indicates 
the presence of at least six isoprenyl groups in the ligand (Figure 15, A). The 
positive MS/MS spectrum is characterized by the presence of two ions with 
m/z of 197.1 and 235.2 typical of the fragmentation of ubiquinones [60], 
known as tropylium and pyrylium ions respectively (Figure 15, B). Based on 
these data, it was possible to identify the ligand of the GNA1030 protein as 
the ubiquinone 8, also known as coenzyme Q8 (Figure 15, C). 
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Figure 15: (A) and (B) MS/MS spectrum of the ligand in negative (A) and positive mode (B). (C) 
Structure of the ubiquinone 8 showing the position of the isoprenyl groups, the two methyl 
groups (red squares) as well as the position of the two reporter ions (Pyrilium and Tropylium) 
observed after collision-induced dissociation in positive mode. 
A 
B 
C 
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The ubiquinone 8 has also been identified as the ligand of GNA1030 purified 
from the cytoplasm of E. coli (recombinant protein expressed without the 
signal sequence) as well as from the periplasm of MenB. The presence of the 
same molecule associated to the GNA1030 protein purified from different 
organisms and different cellular compartments suggests that the protein 
binds the ligand specifically. 
E. coli YceI, one of the closest homologs of GNA1030, is a periplasmic 
protein that is induced by high pH [61] and high salt concentration [62]. The 
upstream gene adjacent to yceI encodes for the putative cytochrome b561, 
which is a member of PF01292 or the cytochrome b561 family in the Pfam 
database. The genes of this family and the GNA1030 homologs often exist as 
neighbors, such as in Bacillus subtilis, Vibrio cholerae, Pseudomonas 
aeruginosa, Yersinia pestis, Mesorhizobium loti, and Xylella fastidiosa. One 
of the open reading frames of Caulobacter crescentus encodes a fusion of 
the two proteins. Thus, it is likely that members of the YceI like family of 
proteins play a role in the electron transport system by binding polyisoprenoid 
molecules [58]. In the case of GNA1030, the upstream gene does not encode 
for a cytochrome but for an enzyme involved in leucine biosynthesis. The 
GNA1030 protein can also act as a carrier of the ubiquinone 8 from the 
cytoplasm to the periplasm, or can be involved in the stress response of the 
bacteria (the coenzyme Q8 possesses strong antioxidant capabilities) [60], 
[63]. In conclusion data from native mass spectrometry allowed us to assign 
a putative function to an uncharacterized protein vaccine candidate.  
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Characterization of the mass decrease found on SAL1486 
SAL1486 is the backbone pilus subunit of Streptococcus agalactiae Pilus 
Island 2a. S. agalactiae, also known as Group B Streptococcus (GBS), is a 
Gram-positive pathogen that causes life-threatening pneumonia, sepsis, and 
meningitis in newborn and young infants [64]. This microorganism is classified 
into 10 capsular polysaccharide serotypes, each antigenically and structurally 
unique. Although major efforts have been made in the development of 
multivalent capsular conjugate vaccines, there is currently no vaccine against 
GBS [65]. To overcome serotype-specific immunity and the increasing 
number of nontypeable isolates, vaccines based on conserved protective 
proteins are highly desirable [66]. Recently, three pilus types have been 
discovered in GBS as important virulence factors as well as potential vaccine 
candidates [67]. The genes involved in pilus assembly are clustered in 
characteristic genomic loci, named Pilus Island (PI), specifically PI-1, PI-2a 
and PI-2b, each encoding three proteins containing a LPXTG motif, 
representing the structural components of the pilus, and two sortase 
enzymes, catalyzing protein polymerization. Each of the three pilus types 
carries two protective antigens [67] and among these the backbone protein of 
pilus type 2a (SAL1486 or BP-2a), is able to significantly mediate 
opsonophagocitic activity and to confer protection in mice only against strains 
expressing the homologous allele. The crystal structure of this protein (Figure 
16, ∼190 aa from the N terminus (D1 domain) were absent in the crystal, D1 
is likely to be cleaved off during crystallization [68]), reveals three IgG-like fold 
domains (namely D2 (residues 190–332), D3 (residues 333–455), and D4 
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(residues 456–641), each one characterized by a putative stabilizing 
isopeptide bond.  
 
Figure 16: Ribbon representation of BP-2a at 1.75 Å showing the position of the three putative 
isopetide bonds (ball and stick rapresentation). 
 
Isopeptide bonds are amide bonds with the same structure as peptide bonds 
(from the Greek isos, meaning equal), but formed between the sidechains of 
two aminoacids, at least one of which is not an α-amino or α-carboxy group. 
The best known examples involve the ɛ-amino group of Lys in reaction with a 
main chain α-carboxy group [69]; however, variations involving side chain 
carboxy or carboxyamide groups also occur. Isopeptide bonds formed 
through lysine residues mediate several crucial biological processes triggered 
45 
 
 
 
by the intermolecular cross-linking of proteins. Examples include 
ubiquitylation [70], sumoylation [71], sortase-mediated cell surface protein 
anchoring [72] and pilus formation [73], [74]. Although they differ in details, 
these processes share several features:  
(i)  all involve the reaction of a Lys ɛ-amino group on one protein with a 
main chain α-carboxy group on the other. 
(ii) all are enzyme-mediated, and involve a transient thioester intermediate 
formed by the catalytic residue Cys present in the active site of the 
participating enzyme. This intermediate is then resolved through 
nucleophilic attack by the lysine ɛ-amino group to complete an 
isopeptide bond. 
In contrast to these enzyme-dependent processes, one example is known 
where inter-molecular isopeptide bonds form autocatalytically. This occurs 
during capsid assembly of the Escherichia coli bacteriophage HK97, in which 
a precursor form of the viral capsid undergoes expansion and reorganization. 
In this maturation process, isopeptide bonds are formed between Lys and 
Asn residues of different subunits, resulting in covalent rings of protein 
subunits that are topologically linked into protein chain mail [75].  
It was in 2007 that intramolecular isopeptide bonds were first discovered in 
the crystal structure of Spy0128, the protein that forms the polymeric shaft of 
the pili present in Streptococcus pyogenes serotype M1 [69]. Continuous 
electron density joining the side chains of Lys36 and Asn168 in the N-terminal 
domain and Lys179 and Asn303 in the C-terminal domain suggested the 
presence of isopeptide bonds joining each Lys–Asn pair. These bonds were 
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confirmed by mass spectrometric analysis of both the recombinant protein 
and the native pili. Both bonds were buried in the hydrophobic cores of their 
respective domains and were associated with a neighboring Glu residue 
(Glu117 and Glu258, respectively) whose carboxyl group was hydrogen bonded 
to the isopeptide moiety. In each case, the substitution of the acidic residue 
by Ala resulted in the loss of the isopeptide bond, indicating that the bonds 
were generated by an autocatalytic, single-turnover intramolecular reaction 
catalysed by the Glu residue (Figure 17). 
 
 
 
Figure 17: Intramolecular isopeptide bond between Lys
36
 and Asn
168
 on Spy0128 (A, red circle) 
and scheme of its formation (B) 
 
Recent crystallographic and mass spectral analyses of protein subunits from 
Gram-positive pili indicate that intra-molecular isopeptide bonds like those 
observed in Spy0128 are present in all major pilin subunits so far analyzed, 
despite wide variations in sequence, size and domain organisation. Thus, the 
shaft-forming major pilins from Corynebacterium diphtheriae (SpaA) [76], 
Bacillus cereus (BcpA) [77] and Streptococcus pneumoniae (RrgB) [68] 
follow the pattern seen in Spy0128; therefore internal isopeptide bonds are a 
consistent feature of the pilus shafts.  
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The mass difference found on the SAL1486 protein is compatible with the 
presence of three isopeptide bonds (- 17 Da x 3 = - 51 Da), as hypothesized 
by crystallographic study. Thus, a specific MS-based approach was 
developed to confirm the presence of these three post-translational 
modifications. For this purpose, the full length SAL1486 was expressed and 
purified from E. coli. The strategy consists in the complete digestion of the 
recombinant BP-2a using the endoprotease Lys-C, followed by the mass 
spectrometry analysis of the proteolysis products. In order to easily sort-out 
and identify the cross-linked peptides (containing the isopetide bonds), a C-
terminal derivatization strategy of the digestion products was developed. The 
digestion products were treated with O-methylisourea that modifies the C-
terminal lysine in homoarginine, leading to a mass increase of 42 Da for each 
modified C-terminal extremity. Since the cross-linked peptides contain two C-
terminal extremities, their derivatization lead to a double mass shift (i.e. +84 
Da) (Figure 18).  
 Enhance sequence coverage and Lys Modification: 
Guanidination
Sample Desalting
A B
 
Figure 18: (A) scheme of the derivatization reaction of a C-terminal lysin with O-methylisourea.     
(B) Example of the mass spectra of a peptide containing an isopeptide bond before and after the 
derivatization step (in blue and in red, respectively). 
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When “in solution” digestion was performed, the SAL1486 protein was found 
to be particularly resistant (with the exception of the D1 domain). The best 
proteolysis and so the larger sequence coverage was obtained by “in gel” 
digestion with Lys-C after SDS-PAGE of entire recombinant forms, probably 
for the strong denaturing effect of the SDS. The peptides produced by the 
digestion were either directly analyzed by MALDI-ToF mass spectrometry 
(Figure 18, upper panels) or were modified with O-methylisourea prior the 
analysis (Figure 18, lower panels). Comparing the two spectra obtained it 
was possible to identify three isopeptide bonds, one for each domain except 
for D1. The involved aminoacids are Lys199 and Asn325 in the D2 domain 
(Figure 19, A), Lys355 and Asn437 in the D3 domain (Figure 19, B), and Lys463 
and Asn636 in the D4 domain (Figure 19, C). The surrounding area around 
these bonds is largely hydrophobic, comprising several aromatic residues, in 
agreement with observations made for the isopeptide bonds in several pilus 
proteins. Each of the four domains appears to fold independently, as 
demonstrated by expressing and purifying each domain, selecting the N and 
C termini based on the domain boundaries defined in the crystal structure of 
SAL1486 (Figure 16). All four domains were expressed in soluble form in E. 
coli, and MS analysis of tryptic digests of D2, D3, and D4 revealed that the 
domains carried the same isopeptide bonds found in the full-length protein. 
This finding suggested that the overall structural organization of the 
independently expressed domains was sufficiently preserved to bring the 
lysine and asparagine residues at a suitable distance and allow the 
autocatalytic reaction [78]. 
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Figure 19:  Identification of internal isopeptide bonds by MALDI TOF mass spectrometry. 
The recombinant protein BP-2a was run on a 4-12% acrylamide SDS-PAGE. The protein was “in gel” 
digested with Lys-C. The peptides produced by the digestion were either directly analyzed by MALDI 
TOF mass spectrometry (upper panel) or were modified with O-methylisourea prior the analysis (lower 
panel). Isopeptide in D2 domain was evidenced by the molecular ion of m/z 4040.85 (A, upper panel) 
that was in agreement with the molecular mass of peptide 
190
NTETKPQVDKNFADK
204
 linked by an 
isopeptide bond to the peptide 
307
ITYSATLNGSAVVEVLETNDVK
328
 (expected molecular mass 
4040.07 Da). The reaction of guanidination induced a signal mass shift of 42 and 84 Da corresponding 
to a single and the double C-terminal peptide derivatization, respectively and confirmed the linkage of 
the two peptides (A, lower panel). By the same way, isopeptide bonds in domains D3 and D4 were 
assigned from the ion of m/z 2145.18 in agreement with the molecular mass of peptide 
351
ITVNKTWAVDGNEVNK
366
 linked to peptide 
437
NNK
439
 (expected molecular mass 2145.13 Da ) 
and from the ion of m/z 1762.05 in agreement with the molecular mass of the peptide 
461
FVKTNK
466
 
linked by an isopeptide bond to the peptide 
630
DAQQVINKK
638
 (expected molecular mass 1761.90 
Da), B and C upper panels, respectively. The reaction of guanidination confirmed the covalent linkage 
of the peptides by inducing the double mass shift of 42 and 84 Da (lower panels).  
(?) Trypsin autodigestion product.  (*) Peak not identified. 
 
Finally, to evaluate the function of these isopeptide bonds in the antigenicity of 
BP2-a, the wild type protein and a mutated form of BP2-a (in which the three 
lysine residues involved in the isopeptide bonds were substituted into alanine 
residues) were both tested in a mouse maternal immunization model. Two 
groups of adult female CD1 mice were immunized with the purified 
recombinant proteins (with and without isopeptide bonds). After three 
immunizations, mice were mated and the resulting offspring were challenged 
with a dose of GBS calculated to kill about 90% of the pups. The high levels of 
protection observed with the mutated form of the protein revealed that the loss 
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of isopeptide bonds does not interfere with the capacity of the protein to 
confer protection in mice and to elicit opsonic antibodies (Figure 20) [78]. 
 
Figure 20:  Comparison between the wild type and the mutated form of SAL_1486  
(A) SDS/PAGE of purified recombinant wild type BP-2a-515 containing intramolecular isopeptide 
bonds (BP-2awt) and BP-2a-515K199A/K355A/K463A, the mutant form lacking the ability to form 
IPs. The mutant protein showed an electrophoretic mobility slower respect to the naive form. (B) 
Opsonophagocytosis activity of mice antisera raised against BP-2awt and BP-2a-
515K199A/K355A/K463A in the presence of phagocytic HL60 cells and baby rabbit complement by 
using Group B Streptococcus strain 515. A 1:30 dilution serum was used in this assay. The log10 
difference between Group B Streptococcus CFUs at time 0 and time 1 h are shown. The antigens used 
are recorded above each bar. White bars represent preimmune sera from the same animals; error bars 
indicate standard deviation of three indipendent experiments. 
 
Isopeptide bonds in SdrC, an adhesin from S. aureus  
In addition to pilus-associated proteins, other cell-surface adhesins are now 
known to contain intra-molecular isopeptide bonds. One example is the 
Staphylococcus aureus adhesin Cna that possesses isopeptide bonds in both 
its collagen-binding A region (CnaA domain) and its repetitive B domains 
(CnaB domains) [69]. Other examples include the adhesin Ace from 
51 
 
 
 
Enterococcus faecalis [79], the Streptococcus gordonii antigen I/II adhesin 
SspB, which has Lys–Asn isopeptide bonds in its two C-terminal CnaA-type 
domains [80], and the fibronectin-binding protein FbaB from Streptococcus 
pyogenes, which contains a Lys–Asp bond in one of its CnaB domains [81], 
[82]. The presence of isopeptide bond in bacterial pili and in multidomain 
adhesins suggests a crucial role not only in resisting mechanical stress, given 
that these long, thin adhesive structures experience strong tensile forces 
along the long axis during host cell attachment, but also in the protection 
against proteolysis. Since the attention given to this type of PTMs is 
continuously growing, especially in the vaccine field where the 
characterization of the virulence factors is of pivotal importance, a MS-based 
approach to rapidly assess the presence of isopeptide bonds has been 
developed and applied to the Staphylococcus aureus adhesin SdrC.  
A critical factor for the pathogenic success of Staphylococcus aureus 
depends on its ability to adhere effectively to multiple host tissues [83], [84]; 
the adhesins mediating staphylococcal adherence and colonization often 
target the extracellular matrix of the host and hence belong to the 
MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix 
Molecules) family [85]. This class of proteins is typified by the S. aureus 
adhesin Cna and shares a similar structural organization. These proteins 
contain an amino terminal signal sequence followed by an A-region that often 
harbors the ligand-binding sites (ligands are matrix molecules such as 
fibrinogen and collagen). The A-region is comprised of sub-domains (CnaA 
domains) adopting an immunoglobulin G-like (IgG-like) fold. Sometimes the 
A-region is followed by a B-region containing repeated β-sandwich modules 
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of unknown function (CnaB domains) [62]. In the case of the Sdr subfamily of 
staphylococcal MSCRAMMs, the B-region is accompanied by a repeat 
domain composed of multiple Ser-Asp dipeptide repeats (SD-repeat or Sdr); 
SdrC is one of the proteins of this subfamily [86]. Since the presence of 
isopeptide bonds has already been reported in the Cna protein (both in the 
CnaA and CnaB domains), as well as in others members of the MSCRAMM 
family, it has been hypothesized their presence by sequence similarity into 
the CnaB domains of the SdrC protein. For this study the region containing 
the CnaB domains was expressed in E. coli and purified, and the 
recombinant protein (named SdrC CnaB) was analyzed by denatured MS. 
The purpose of this analysis was to measure the intact molecular weight 
since for each isopeptide bond present, the mass of the proteine decrease of 
17 Da. 
Molecular weight specie A: 26690.5 Da
Molecular weight specie B: 26673.2 Da
m/z
600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
m/z780 790 800 810
 
Figure 21:  ESI MS spectra of the SdrC CnaB protein in denatured conditions 
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The spectrum in figure 21 evidences the presence of two species with a 
molecular weight (MW) of 26690.5 Da and 26673.2 Da, respectively (error: 
3.7 ppm). The first one is the SdrC CnaB protein (expected MW 26690.4 Da) 
while the second one is the same protein with a mass reduction of about 17 
Da (no other proteins were identified in the sample after in solution digestion 
with trypsin and LC-MS/MS analysis). This mass reduction is compatible with 
a loss of a NH3 group somewhere in the protein and it can be due to a 
deamidation (succinimide conversion of an asparagine or a glutamine 
residue) or to the formation of an isopeptide bond. To discriminate between 
these two cases the protein dynamic in solution was investigated using 
hydrogen-deuterium exchange mass spectrometry (HDX-MS). This technique 
takes advantage of a natural process occurring when a protein is in solution; 
hydrogen located on polar side chains or at the N/C termini and bonded to 
heteroatoms such as –N, -O, or –S exchange quite easily with hydrogens in 
the surrounding solvent. This H→H conversion cannot be detected by mass 
analysis. In contrast, exposing a protein to a D2O-containing environment 
leads to H→D replacements that increase the mass of the protein by one unit 
per exchange event [87]. The reaction is then quenched and analyzed by 
MS, these steps are performed in an aqueous solution, which means that 
exchange will continue at a slow rate leading to a partial reversion of 
deuterated positions after the quench step; this process is referred to as 
back-exchange. Although HDX takes place also at side chains, the back 
exchange of these hydrogens is so fast that is not compatible with the 
timescale of the experiment, thus only the backbone amide hydrogens, that 
require a longer time both for the exchange and the back exchange, are 
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taken in account for the analysis. Every residue (with the exception of 
prolines and the N-terminal amino acid) possesses an amide N–H group, and 
therefore HDX can probe features affecting the entire protein. Isotope 
exchange is fastest for completely solvent-exposed amides that are not 
involved in hydrogen bonding and located on the surface of the protein. The 
rate constant of N–H→N–D conversion measured is referred to as kex 
(“exchange” rate constant). For each individual amide N–H, the value of kex is 
determined by the flanking side chains, as well as the pD (pH=pD+0.4), the 
temperature and the ionic strength of the solvent. HDX can proceed with acid 
or base-catalysis, and kex has its minimum around pH 2.5 (for the amide 
hydrogens). Catalysis by OD− is most prevalent under typical conditions. 
Above pD 3, kex increases by one order of magnitude with each pD unit, 
reaching values on the order of 103 s−1 at pD 9 [88]. The possibility to tune kex 
by controlling the pH of the solvent is crucial for many HDX/MS strategies. 
Key to the application of HDX for structural studies is the fact that the N–
H→N–D conversion rate is modulated by the conformational properties of the 
protein. Ordered regions possess a multitude of intramolecular hydrogen 
bonds that reduce the solvent accessibility of many amide sites; thus the 
overall rate constant kHDX is much smaller than kex. The corresponding 
protection factors P=kex/kHDX sometimes exceed 10
6 for natively folded 
proteins. Nonetheless, even protected amides can undergo HDX at 
measurable rates. These exchange events are mediated by conformational 
fluctuations of the protein. Specifically, isotope labeling can only occur during 
short-lived transitions to an “open” conformation. The ongoing occurrence of 
opening/closing events is a manifestation of the protein thermal motions. 
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Some of these structural fluctuations may represent events that are quite 
localized, whereas others are more global. Rate constants of the opening and 
closing transitions are designated as kopen and kclosed, respectively. The 
overall exchange mechanism can thus be described as in Figure 22. 
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Figure 22:  Schematic mechanism of HDX 
 
 
This methodology allows us to investigate the mass difference found in the 
SdrC CnaB protein by comparing the dynamic of the two species present in 
the sample. The rationale is that the presence of a deamidation should not 
affect the overall dynamic of the protein (Figure 23, A). On the other hand an 
internal isopeptide bond can block a region of the protein reducing its 
capability to switch to an “open” conformation resulting in a protection effect 
of the hydrogens present in that region and therefore in a difference in the 
overall deuteration pattern and a significative decrease in the number of 
incorporated deuteron in comparison with the form without the isopeptide 
bond (Figure 23, B).  
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Figure 23:  Schematic mechanism of HDX of a protein with a deamidation (A) or with an 
isopeptide bond (B) 
 
To test this hypothesis, the averaged deuterium exchange behavior of the 
SdrC CnaB protein was measured at seven time points (from 30 seconds to 
8.5 hours). The mass spectra of the +32 charge state of the two forms of the 
protein in some of the time points analyzed is reported in Figure 24 A; the 
deuteration was performed at 0 °C in order to decrease the global exchange 
rate and increase the resolution at lower time-points. After the deuteration, 
the mass difference between the two forms of the protein is constant for all 
the time points and it is about 50 Da (Figure 24, B and C).  
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Figure 24:  Global HDX-MS analysis of the SdrC CnaB protein  
(A) Mass spectra of the +32 charge state of SdrC at different time points (FD. Fully deuterated). The 
labeling was performed at 0° to increase the resolution at lower time-points. The lines are provided for 
visual guidance. (B) Deconvoluted spectrum of SdrC prior (on the left) and after 8.5 hours of 
deuteration (right panel). The mass difference between the two species change from 17 Da to 50 Da. 
(C) Estimation of the number of deuterons incorporated from the two species. The excel-based 
program HDX-Express was used to extract the centroid mass of each charge state as a function of the 
labeling time.  
 
The mass difference between the two species after the deuteration is higher 
than the one expected for a deamidation suggesting that the initial difference 
of 17 Da is due to an intramolecular isopeptide bond. 
 
A B 
C 
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2.2 Development of MS-based approaches to identify 
unknown PTMs in pathogenic bacteria 
Introduction 
Recently, heightened attention has been drawn towards post-translational 
modified proteins in pathogenic bacteria. While the full significance of protein 
modifications has yet to be precisely defined in prokaryotic systems, post-
translational modifications (PTMs) provide additional sources for protein 
structural and functional diversity. Thus, in a number of human pathogens 
such as Streptococcus agalactiae and Campylobacter jejuni [89], PTMs 
localized on surface proteins have been shown to be directly involved in 
adhesion, colonization, pathogenicity and virulence. Therefore, modified 
surface proteins are now considered for vaccine candidate selection. 
MS represents a powerful tool for detecting and mapping PTMs since this 
processing step leads to a mass modification relative to the theoretical 
molecular weight of the protein. PTMs identification by MS is generally 
achieved using a two steps analytical strategy. First, the presence (and in 
some cases the number) of PTMs is revealed by direct mass measurement 
of the entire protein. Following this step, the modified regions of the protein 
as well as the nature of the PTMs are further characterized using proteolytic 
digestions in combination with tandem mass spectrometry experiments [90]. 
While this approach sounds very "simple", the identification and 
characterization of PTMs by MS represent a non-trivial task mainly due to the 
diversity of these modifications and the complexity of the samples to be 
analyzed. The main objective of this part of the work was to set-up mass 
spectrometry-based approaches for the identification and characterization of 
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unknown PTMs on the surface proteins of pathogenic bacteria. The pathogen 
used for this analysis was Neisseria meningitidis serogroup B. 
 
Selection of the starting material for PTMs discovery 
Since bacterial membrane proteins are virulence factors that play important 
roles during infections and are well exposed on the surface of the pathogens, 
they are considered as potential vaccine candidates. However, their 
hydrophobic nature makes them difficult to study and requires specific 
enrichment methods. 
To select the best starting material for PTMs discovery, a classical 
preparation of membrane proteins extracted with sodium carbonate was 
compared with a preparation of outer membrane vesicles (OMVs) obtained 
with the N. meningitis MC58 Dgna33 mutated strain [91]. This strain is 
deleted for the gna33 gene, involved in membrane assembly/septation, and 
is able to release spontaneously relevant quantities of OMVs into the growth 
medium without requiring any chemical/physical treatment. Both samples 
were separated by SDS-PAGE and the main bands were identified by MALDI 
peptide mass fingerprint after in gel digestion.  
Figure 25 shows the comparison between the OMVs preparation (lane 2) and 
the preparation obtained after sodium carbonate extraction (lane 1). The 
OMVs were selected for PTMs discovery as they contain more outer-
membrane proteins and appear less contaminated compared to the classical 
preparation of extracted membrane proteins. 
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51
39
28
19
14
1 M 2
NMB1855 Carbamoylphosphate synthase large subunit IMP 
NMB1341 Pyruvate dehydrogenase subunit E1  CYT 
NMB1301 30s ribosomal protein S1  CYT 
NMB0124 Elongation factor Tu  CYT 
NMB1429  PorA OMP
NMB2039  PorB OMP
NMB0382  Outer membrane protein Class 4  OMP
NMB1636  Opacityprotein OMP
NMB0865 IgA specific serine endopeptidase OMP 
NMB0461 Transferrin binding protein A  OMP 
NMB0182 Outern membrane protein assembly complex, YaeT OMP 
NMB1988 Iron regulated outer membran protein, FrpB OMP 
NMB1949 Transglycosylase SLT domain protein OMP 
NMB1972 Chaperonine GroEL CYT
NMB1332 Carboxy-terminal peptidase IMP
NMB1483 NlpD OMP
NMB1429  PorA OMP
NMB2039  PorB OMP
NMB0382  Outer membrane protein Class 4  OMP
NMB1636  Opacityprotein OMP
 
Figure 25:  SDS-PAGE analysis comparing the main composition of a membrane preparation 
extracted with sodium carbonate extraction (lane 1) and a OMVs preparation from the N. 
meningitis MC58 Dgna33 mutated strain (lane 2).                                                                                
CYT = cytoplasmic; IMP = inner membran protein; OMP = outer membrane protein  
 
Characterization of the OMVs and PTMs discovery 
In order to characterize proteins associated to the vesicles and to identify 
PTMs, a combined proteomic approach was set-up. A part of the OMVs 
preparation was first separated by SDS-PAGE and proteins were identified 
by MALDI peptide mass fingerprints after in gel digestion. In parallel, OMVs 
were directly subjected to trypsin digestion and the generated peptides 
identified by nano-LC/MS/MS. Mass spectra were processed either manually 
or with a local version of the Mascot search engine (using a database 
containing protein sequences deduced from the sequenced MenB genomes, 
downloaded from NCBInr) in order to identify specific neutral losses and/or 
reporter ions corresponding to unknown PTMs (Figure 26). 
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Figure 26:  Schematic overview of the approach used for the identification of PTMs on OMVs 
proteins. 
 
For the total characterization of the proteins present on the OMVs, an in 
solution digestion with trypsin was performed and the peptides were analyzed 
by nanoLC-MS/MS. A total of 60 proteins were identified. Most of the proteins 
(88%) were classified as outer-membrane proteins according to PSORT 
prediction, 4 proteins (7%) were classified as periplasmic and 3 proteins (5%) 
as cytoplasmic (Table 3). 
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 ID Name
NMB2039   major outer membrane protein IB (porB) 
NMB1429   major outer membrane protein IA (porA)
NMB0018   pilin PilE (pilE) 
NMB0382   ompA family protein
gi|120866875   putative lipoprotein (orf 731)
NMB0703   competence lipoprotein comL (comL)
NMB1057   gamma-glutamyltransferase (ggt)
NMB1053   outer membrane protein OpcA (opcA)
NMB0345   conserved hypothetical protein 
NMB1483   LysM domain-M23 peptidase domain protein 
NMB2091   phospholipid-binding domain protein 
NMB0088   outer membrane protein, OMPP1-FadL-TodX family
NMB0550   putative thiol:disulfide interchange protein DsbC 
NMB0707   rare lipoprotein B family 
NMB0928   putative lipoprotein 
NMB0182   outer membrane protein assembly complex, YaeT protein 
NMB0204   lipoprotein, SmpA-OmlA family 
NMB0281   surA-PPIASE domain protein 
NMB0294   DSBA thioredoxin domain protein
NMB0663   outer membrane protein NsgA
gi|2150054   opacity protein
NMB1124   putative lipoprotein 
NMB1030   YceI family protein 
NMB1812   type IV pilus secretin PilQ (pilQ)
NMB0109   LysM domain protein 
NMB1126   CsgG family protein 
NMB1870   lipoprotein NMB1870 
gi|2315235   Opa1800 outer membrane protein 
gi|1841506   opacity outermembrane protein
NMB0700   IgA-specific serine endopeptidase
NMB1309   type IV pilus biogenesis-stability protein (pilF) 
NMB1497   TonB-dependent receptor
NMB1567   macrophage infectivity potentiator 
NMB0460   transferrin-binding protein
NMB2132   transferrin-binding protein-related protein
NMB0992   adhesin
NMB1519   thiol:disulfide interchange protein DsbD 
NMB0181   outer membrane protein OmpH, putative 
NMB1961   VacJ-related protein
NMB1398   Cu-Zn-superoxide dismutase
NMB1985   adhesin
NMB0783   conserved hypothetical protein 
NMB0346   conserved hypothetical protein 
NMB2095   conserved hypothetical protein 
NMB0035   conserved hypothetical protein
NMB1557   conserved hypothetical protein
NMB1125-1163   hypothetical protein NULL
NMB2139   conserved hypothetical protein
NMB0039   hypothetical protein
NMB1963   conserved hypothetical protein
NMB1620   conserved hypothetical protein
NMB2147   hypothetical protein
NMB1468   hypothetical protein
NMB1946   D-methionine ABC transporter, periplasmic D-methionine-binding protein (metQ) 
NMB0634   iron(III) ABC transporter, periplasmic iron(III)-binding protein (fbpA)
NMB0355   lipopolysaccharide ABC transporter, periplasmic lipopolysaccharide-binding protein (lptA) 
NMB1332   C-terminal processing peptidase
NMB1285   phosphopyruvate hydratase (eno) 
NMB0124   translation elongation factor Tu (tuf) 
NMB1972   chaperonine GroEL
Cytoplasmic Proteins
Periplasmic Proteins
Outer Membrane Proteins
 
Table 3: Proteins identified on MenB OMVs. 
Tryptic peptides were separated off-line using a strong cationic exchange resin prior to nano-LC-
MS/MS analysis. Mass spectra were processed with a local version of the Mascot search engine using a 
database containing protein sequences deduced from the sequenced MenB genomes, downloaded from 
NCBInr. 
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Due to the high number of membrane proteins identified, these proteins 
should be carefully considered as components of the membrane 
compartment. After automatic analysis of the MS/MS data with MASCOT, the 
unidentified spectra were all manually interpreted in order to select MS/MS 
spectra of peptides containing a neutral loss or a reporter ion with a mass 
corresponding to the mass difference observed between the modified and 
unmodified peptide (Figure 27). 
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Figure 27:  Rationale of the mass spectrometric approach used to indentify new PTMs (CID, 
collision induced dissociation) 
 
Using this strategy two modified peptides, belonging the protein encoded by 
the orf 731 (Figure 28, A) and the NMB 0382 (Figure 28, B) displaying a delta 
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mass of 166 Da, have been identified. In both cases, the fragmentation 
pattern contains a reporter ion with an m/z value of 167. The peptides were 
fully sequenced and the modified residue was identified as a cysteine. This is 
the first time that such a modification is reported thus suggesting the 
presence of a new type of PTM. 
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Figure 28:  MS/MS spectra of the peptides carrying the putative PTM (orf 731 panel A, NMB 
0382 panel B). The reporter ion is highlighted (green ellipses). 
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Because of their surface localization, these two proteins could be considered 
as potential vaccine candidates. 
The orf731 codify for a putative lipoprotein well conserved among different 
neisserial strains. In literature there are no available data about this protein. In 
the Pfam database this protein, belong to the MliC (membrane bound 
lysozyme inhibitor of c-type lysozyme) superfamily, this family of proteins 
possesses lysozyme inhibitory activity and confers increased lysozyme 
tolerance [92]. Lysozyme is part of the innate immune system, it is an enzyme 
that hydrolyze the peptidoglycan by cleaving the glycosidic bond that 
connects N-acetylmuramic acid with the fourth carbon atom of N-
acetylglucosamine; it is abundant in a number of secretions, such as tears, 
mucus, human milk, and especially saliva. Bacteria have evolved various 
mechanisms to evade this bactericidal enzyme, one being the production of 
lysozyme inhibitors. Since the ecological niche of Neisseria meningitidis is the 
human nasopharynx where it is continuously exposed to lysozyme, it is 
possible to hypothesize a crucial role of the protein coded by the orf731 in the 
protection against this enzyme.   
NMB0384 is a class 4 outer membrane protein known also as RmpM [93]. 
NMB0384 is highly conserved in all serogroups of N. meningitidis (around 
99% sequence identity) and shares 94% sequence identity with its 
gonococcal orthologue, protein III. The NMB0384 sequence can be divided 
into four parts: a 22-residue signal sequence which is cleaved by a signal 
peptidase during translocation of the protein to the periplasm, an N-terminal 
domain of approximately 40 amino acids, followed by a 20-residue hinge 
region rich in proline. The C-terminal domain of RmpM consists of 
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approximately 150 amino acids sharing 35% sequence identity with the C-
terminus of E. coli OmpA, and is therefore called an OmpA-like domain. C-
terminal, OmpA-like domains, found in many Gram-negative bacterial 
proteins, have been suggested to associate non-covalently with peptidoglycan 
[94], [95]. Although NMB0384 has been identified as an outer membrane 
protein, it is not clear how it associates with the outer membrane. NMB0384 
has no modifiable N-terminal cysteine residue which could accept a lipidic 
moiety, and the N-terminal part of the protein encompasses only 40 amino 
acids, which is too short to form a monomeric transmembrane β-barrel 
structure. However, this protein fractionates with outer membranes [96] and 
has been shown to interact with integral outer membrane proteins. NMB0384 
forms heterooligomeric complexes with the two meningococcal major porins, 
PorA and PorB [97], and with the TonB-dependent transporters, TbpA 
(transferrin binding protein A) and LbpA (lactoferrin binding protein A) [98]. 
Because NMB0384 contains an OmpA-like domain and is able to interact with 
outer membrane proteins, it can work as a structural protein, linking the outer 
membrane to the peptidoglycan layer [95] and [98]. This link is essential for 
the integrity of the cell. For example, a DompA-lpp E. coli strain, lacking both 
OmpA and the major outer membrane lipoprotein which interacts covalently 
with peptidoglycan, shows defects such as hypersensitivity to toxic 
compounds, the release of periplasmic proteins and the formation of outer 
membrane vesicles [99]. A DNMB0382 N. meningitidis strain does not show 
such severe defects: the mutant has the same morphology and growth 
characteristics as the parental strain [90]. This suggests that other proteins 
can fulfill the role of NMB0384 in N. meningitidis. 
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The + 166 Da modification found on these proteins still need to be 
characterized but, since in both the proteins the modified residue is a cysteine 
not included in any functional domain, the putative PTM seems to be not 
directly involved in their functions. Nevertheless, further analyses are required 
in order to confirm the presence of this putative modification and to assign a 
possible chemical structure and a biological and immunological function. 
 
3 Conclusions 
In the reverse vaccinology process, protein vaccine candidates are selected 
following 4 main steps: (i) antigen selection; (ii) cloning/expression of the 
selected genes and purification of the recombinant forms of the antigens; (iii) 
in vitro and in vivo assays to define protection and toxicity; and (iv) structural, 
functional, epidemiological and immunological characterizations of the 
recombinant antigens that demonstrates protection in animal model and no 
toxicity. In spite of the success of the reverse vaccinology, several aspects 
that could not be assessed by the approach are currently emerging. One of 
these aspects is the impossibility to obtain information about the post-
translational modifications (PTMs) of the putative vaccine candidates. 
Moreover the necessity to use heterologous recombinant proteins may 
results in changes in the maturation, compared to the native proteins, which 
can affect their immunogenicity. 
Overexpression of a protein in a foreign host, such as Escherichia coli, is 
frequently the first step toward biochemical, enzymatic, and structural studies 
and is instrumental when purification from the natural source(s) is hardly 
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achievable. High-level production of functional heterologous proteins in E. 
coli often remains difficult in spite of the improvements achieved in the past 
decade. Indeed, heterologous protein overexpression in E. coli continues to 
be a challenging task for proteins possessing numerous disulfide bridges 
and/or being the target of post-translational modifications or when genes 
enriched in rare codons (i.e., codons that are used with very low frequency in 
this host) have to be expressed. Despite these limitations, bacterial 
expression often yields reasonable amounts of proteins that can then be 
extensively studied to get biological and structural insights. The key issue in 
these studies is to obtain large amounts of the purified recombinant protein 
with a homogeneity as high as possible prior to proceeding to its biochemical, 
functional and structural characterization. This requirement is deeply 
interconnected with the necessity of precisely determining the identity of the 
recombinant protein and of fully unraveling its primary structure, as well as 
with the need of unveiling any possible chemical modifications leading to 
undesirable microheterogeneities. 
Traditional approaches used for quality control of recombinant proteins are 
based on bottom-up proteomics methodologies. Although a wealth of 
literature reports pointed out the successful use of this approach, the latter 
suffers from some limitations when it comes to determining the full complexity 
of a protein sample. For this purpose the top-down MS/MS approach has 
been developed. This combines the measurement of the intact experimental 
mass with the recording of MS/MS data on the full-length protein. Such a 
technique is becoming more and more popular since it allows an extensive 
description of protein properties. In addition to this “classical” mass 
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spectrometry approaches, together with equally spectacular advances in 
mass spectrometric instrumentation, a new field has emerged, termed native 
protein mass spectrometry, which focuses on the structural and functional 
analysis of the dynamics and interactions occurring in protein complexes. 
Native MS gives information about the composition, topological 
arrangements, dynamics, and structural properties of protein complexes. The 
mass range is theoretically unlimited and highly dynamic, allowing the 
detection of small subunits and large complexes within the same 
measurement and the amount of protein needed for an analysis is, compared 
to most other structural biology methods, very low. In the past years, the use 
of this methodology led to exciting applications ranging from the detailed 
study of equilibria between different quaternary structures as influenced by 
environmental changes or binding of substrates or cofactors, to the analysis 
of intact nano-machineries. 
 
The first part of the work herein presented is related to the development of 
mass spectrometry-based approaches to study the maturation of 
recombinant proteins and the application of these methods to proteic vaccine 
candidates. I analyzed seven recombinant proteic vaccine candidates, 
belonging to three pathogenic microorganisms (Table 1). All the proteins 
were expressed in E. coli, purified avoiding denaturing steps and their 
oligomerization state was assigned using native MS (Table 2). Among the 
proteins tested, three were found monomeric (GNA2091, fHbp and 
SAL1486), two were dimeric (GNA1030 and NadR, as suggested in [45]) and 
one was trimeric (NadA, as suggested in [46]). Three proteins (PSL1, 
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GNA1030 and SAL1486) presented a mass difference between the expected 
and the observed MW and required further investigations.  
PSL1 was present in two forms: a covalent dimer, through a disulfide bridge, 
and a monomer with a mass increase of 765.6 Da, also linked through an S-
S bond. Both these modifications are not physiological since the only 
cysteine present in the protein is covalently attached, in nature, to a 
diacylglycerol moiety. In order to characterize the modification, the protein, 
with and without reducing agent, was analyzed by MALDI-ToF MS in 
negative ionization mode and a signal at 766.6 m/z (MW of 767.6 Da) was 
present only in the reduced sample (Figure 10) and was identified as the 
coenzyme A (MW of 767.5 Da). In literature is already reported that 
molecules with free thiols are able to link to protein cysteine through disulfide 
bonds (S-thiolation) [50]; this modification is commonly observed in 
recombinant proteins secreted from E. coli cells. Various thiol modifiers have 
been identified by MS including glutathione, gluconoylated glutathione, 4-
phosphopantetheine, dephosphorylated coenzyme A and coenzyme A. S-
thiolation in this case can be a response to environmental stress experienced 
by the cells during the high cell density growth, or to the (patho)-physiological 
burden brought on by the expressed proteins. Moreover, the attachment of 
the CoA could affect the immunogenicity of the protein, since the structure of 
this molecule is similar to some TLR agonists (Figure 11) [51]. Thus the 
ability of the modified and unmodified PSL1 to activate the TLRs has been 
tested but no differences has been found between the two samples (data not 
shown), indicating that the CoA does not possess an adjuvant activity. To 
avoid any risk a mutated form of the protein, with the deletion of the cysteine 
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residue, has been generated. The mutated protein is still able to confer 
protection in mice immunization models and, after native MS analysis, 
showed a monomeric oligomerization state and an observed MW in 
agreement with the expected one.  
The mass increase found on the GNA1030 instead (+ 1457 Da) is present 
only in the native MS analysis thus indicating a non covalent modification. 
Since in literature is reported that many homologs of this protein are able to 
bind a lipid molecule (Figure 12) [57], [58], [59], has been hypothesized that 
also GNA1030 is bound to a small molecule that is responsible for the 
increase of MW in native conditions. This hypothesis has been demonstrated 
by in source fragmentation during the native MS analysis of the protein, 
showing the presence of a small ligand, with a MW of about 728 Da, non-
covalently bound to the GNA1030 protein with a 1:1 stoichiometry (Figure 
13). In order to fully characterize the ligand, the correspondent ion has been 
selected and fragmented, in both positive and negative mode (Figure 15, A 
and B respectively). Based on these data, it was possible to identify the 
ligand as the ubiquinone 8 (Figure 15, C). The ubiquinone 8 has been also 
identified as the ligand of GNA1030 purified from both the cytoplasm of E. 
coli and the periplasm of MenB, suggesting that the protein binds the ligand 
specifically. In literature is reported that the genes of the cytochrome b561 
family and the GNA1030 homologs often exist as neighbors, such as in 
Bacillus subtilis, Vibrio cholerae, Pseudomonas aeruginosa, Yersinia pestis, 
Mesorhizobium loti, Xylella fastidiosa, and Caulobacter crescentus [58]. 
Thus, it is likely that these members of the YceI like family of proteins play a 
role in the electron transport system by binding polyisoprenoid molecules. In 
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the case of GNA1030, the upstream gene does not encode for a cytochrome 
but for an enzyme involved in leucine biosynthesis. The GNA1030 protein 
can also act as a carrier of the ubiquinone 8 from the cytoplasm to the 
periplasm, or can be involved in the stress response of the bacteria. This 
represents, in our best knowledge, a first report where native MS was a key 
strategy to define a putative biological role to a protein with unknown 
function. 
Finally the mass difference found on the SAL1486 protein is compatible with 
the presence of three isopeptide bonds (- 17 Da x 3 = - 51 Da), as 
hypothesized by crystallographic study. Thus, a specific MS-based approach 
was developed to confirm the presence of these modifications. The strategy 
developed consists in the derivatization of the C-term extremities of cross-
linked peptides followed by MS analysis. This strategy allowed us to identify 
the three isopeptide bonds hypothesized in SAL1486 protein (Figure 16). 
Moreover, to evaluate the function of these PTMs in the antigenicity of 
SAL1486, the wild type protein and a mutated form of SAL1486 were both 
tested in a mouse maternal immunization model. The results revealed that 
the loss of isopeptide bonds does not interfere with the capacity of the protein 
to confer protection in mice and to elicit opsonic antibodies (Figure 20). Thus 
the isopeptide bonds in this protein are probably required for the resistance to 
mechanical stress and for the protection against proteolysis [78]. 
In addition to pilus-associated proteins, other cell-surface adhesins are now 
known to contain intra-molecular isopeptide bonds. One example is the 
Staphylococcus aureus adhesin Cna that possesses isopeptide bonds in both 
its CnaA and CnaB domains [62]. The high presence of isopeptide bond in 
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bacterial pili and in multidomain adhesins suggests a crucial role of these 
PTMs in the stabilization of such virulence factors. Since the attention given 
to this type of PTMs is continuously growing, especially in the vaccine field, a 
MS-based approach to rapidly assess the presence of isopeptide bonds 
using hydrogen-deuterium exchange has been developed and applied to the 
Staphylococcus aureus adhesin SdrC. The region of the sdrC protein 
containing the CnaB domains was expressed in E. coli and purified, and the 
recombinant protein (named SdrC CnaB) was analyzed by denatured MS. In 
the entire mass spectra two species are present. The first one is the SdrC 
CnaB protein while the second one is the same protein with a mass reduction 
of about 17 Da. This mass reduction is compatible with a loss of a NH3 group 
somewhere in the protein and it can be due to a deamidation (succinimide 
conversion of an asparagine or a glutamine residue) or to the formation of an 
isopeptide bond. To discriminate between these two cases the protein 
dynamic in solution was investigated using HDX-MS. The data obtained 
revealed that the mass difference between the two species after the 
deuteration is bigger than the one expected for a deamidation suggesting that 
the initial difference of 17 Da is due to an intramolecular isopeptide bond.  
Obviously these two strategies can be applied for the assessment and the 
identification of isopeptide bonds in every protein of interest providing useful 
tools in the study of this type of post-translational modifications. 
 
It is clear that native MS may play a vital, and rather unique, role in structural 
biology and particularly in the study of the protein maturation, providing not 
only detailed information about protein complex stoichiometry, but also about 
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the effects on structures and changes in the environment, the binding of 
cofactors, and the interactions and dynamics with other proteins or protein 
complexes, giving in the same time informations about covalent 
modifications. 
 
In the second part of the thesis I applied different MS approaches to identify 
unknown PTMs in Nesseria meningitidis serogroup B surface proteins. As a 
matter of fact, for most bacterial pathogens, the proteins that are likely to 
induce a protective immuno-response are those well expressed and well 
exposed on the cell surface, These proteins have in fact the highest chances 
to come into contact with the host immune system. Therefore a complete 
characterization of the protein composition of the bacterial surface, along with 
their post-translational modifications, is of great relevance in vaccine 
research. However, their hydrophobic nature makes them difficult to study 
and requires specific enrichment methods. To select the best starting 
material for PTMs discovery, a classical preparation of membrane proteins 
extracted with sodium carbonate was compared with a preparation of OMVs 
obtained with the N. meningitis MC58 Dgna33 mutated strain [91]. The OMVs 
were selected for PTMs discovery, as they contain more outer-membrane 
proteins and appear less contaminated compared to the sodium carbonate 
extraction (Figure 25), and fully characterized using a combined proteomic 
approach including both MALDI-ToF/MS and nano LC/MS/MS (Table 3).  
The main issue in the identification of bacterial PTMs is the lack of dedicated 
bioinformatics tools able to identify low represented or unknown 
modifications. Indeed, many approaches were developed to identify peptides 
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and proteins using amino acid sequence information from MS/MS and have 
been extended to identify modified peptides and proteins. However, many of 
them took into account only a few types of PTMs during the analysis, ignoring 
all the others and the investigators had to guess in advance which PTMs 
exist in a sample. Moreover, some search tools compared an MS/MS 
spectrum with all possible combinations of PTMs for each peptide from a 
database, thus, requiring extremely expensive computation.  
In this work, the MS/MS spectra obtained from the characterization of the 
MenB vesicles were then manually processed in order to identify specific 
neutral losses and/or reporter ions corresponding to unknown PTMs (Figure 
27). Using this strategy two modified peptides, belonging the protein encoded 
by the orf 731 (Figure 28, A) and the NMB0382 (Figure 28, B) displaying a 
mass increase of 166 Da, have been identified. In both cases, the 
fragmentation pattern contains a reporter ion with an m/z value of 167 and 
the modified residue was identified as a cysteine. Both the identified proteins 
are outer membrane protein. The orf731 codify for a putative lipoprotein well 
conserved among different neisserial strains that belong to the MliC 
(membrane bound lysozyme inhibitor of c-type lysozyme) superfamily. This 
family of proteins possesses lysozyme inhibitory activity and confers 
increased lysozyme tolerance. Since the ecological niche of Neisseria 
meningitidis is the human nasopharynx where it is continuously exposed to 
lysozyme, it is possible to hypothesize a crucial role of the protein coded by 
the orf731 in the protection against this enzyme. NMB0384 is a class 4 outer 
membrane protein known also as RmpM [93]. This protein is able to interact 
with other outer membrane proteins and possess a C-terminal OmpA-like 
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domain, needed to non-covalently associate with peptidoglycan [94], [95]. Up 
to now, it is not clear how the NMB0384 associates with the outer membrane 
since has no modifiable N-terminal cysteine residue which could accept a 
lipidic moiety, and the N-terminal part of the protein is too short to form a 
monomeric transmembrane β-barrel structure. Because NMB0384 contains 
an OmpA-like domain and is able to interact with outer membrane proteins, it 
can work as a structural protein, linking the outer membrane to the 
peptidoglycan layer [95], [98]. This link is essential for the integrity of the cell; 
for example, a DompA-lpp E. coli strain, lacking both OmpA and the major 
outer membrane lipoprotein which interacts covalently with peptidoglycan, 
shows defects such as hypersensitivity to toxic compounds, the release of 
periplasmic proteins and the formation of outer membrane vesicles [99]. A 
DNMB0382 N. meningitidis strain does not show such severe defects [90] 
suggestsing that other proteins can fulfill the role of NMB0384. This is the first 
time that such a modification is reported thus suggesting the presence of a 
new type of PTM that requires further investigations in order to be fully 
characterized.  
 
In literature there are only few works dedicated to the study of the protein 
maturation in bacteria, especially about PTMs. Therefore, further 
investigations are required to understand not only the type and the number of 
the modifications, but also their biological function. Moreover in the vaccine 
field it is of pivotal importance to study the maturation of the proteic vaccine 
candidates in order to understand their role in parasite-host interaction and 
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their capacity to generate diversity and to influence antigenicity. In this thesis I 
developed different MS approaches to study specific protein modifications 
revealed by the native MS analysis of recombinant proteins. Such molecular 
accidents illustrate the chemically dynamic nature of the cellular milieu and 
emphasize the need to check that any new recombinant protein has the 
expected structure, especially for proteic vaccine candidates. The MS 
methods developed can be then applied to other proteins of interest. In 
addition, I applied the mass spectrometric approach to identify unknown post-
translational modifications on pathogenic bacteria surface proteins reporting a 
putative new PTM on Neisseria meningitidis serogroup B. Due to its sensitivity 
and specificity, mass spectrometry is the methodology of choice for the 
identification and characterization of both covalent and non covalent protein 
modification. Nevertheless, the MS data analysis softwares, to support such 
work, still need to be developed.  
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4 Materials and Methods 
Protein expression and purification 
All the recombinant proteins used in this thesis were produced and purified by 
the Protein Biochemistry Unit of Novartis Vaccines and Diagnostics srl (Siena, 
Italy). 
 
Active immunization 
All the immunizations were performed by the Animal Care Platform of Novartis 
Vaccines and Diagnostics srl (Siena, Italy). 
 
Entire mass analysis in denaturing conditions 
The samples were diluted with formic acid (Sigma-Aldrich, St. Louis, MO, 
USA) 0.1%, with or without 10 mM TCEP (Sigma), and injected into a LC-
20ADXR Prominence HPLC system controlled by a CMB-20A module 
(Shimadzu Corporation, Kyoto, Japan). The protein samples were trapped 
and desalted for 2 min at a flow rate of 220 L/min using a Protein Micro Trap 
column (Michrom BioResources, Inc., Auburn, CA, USA) equilibrated with 
100% buffer A (0.1% formic acid in water). Proteins were directly eluted into 
the mass spectrometer at a flow rate of 60 L/min with 55% solvent B 
(acetonitrile (J.T. Baker, Philipsburg, USA)/water (9/1), 0.1% formic acid). 
Mass spectra were acquired on a Waters Synapt G2 mass spectrometer 
(Waters, Milford, MA, USA) equipped with a standard ESI source using the 
following instrument settings: capillary voltage, 3.0 kV; sampling cone, 35V; 
extraction cone, 4V; source temperature, 80°C; desolvation gas flow and 
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temperature, 600 L/h and 180°C, respectively; cone gas flow, 20 L/h; trap 
collision energy, 4V. Mass spectra were acquired in resolution mode (m/z 
100-2000) and the calibration was performed in positive mode using a 2 
mg/mL cesium iodide (Sigma) solution prepared in 50% isopropanol. The 
spectra were processed with MassLynx 4.1 software (Waters). 
 
Native mass analysis  
For native mass spectrometry, protein samples were buffer exchanged 
against 250 mM ammonium acetate (pH 8.0) using Zeba spin desalting 
columns with a 7-kDa molecular weight cut-off (Thermo Fisher Scientific Inc., 
Waltham, MA, USA). The concentration of each desalted protein was 
measured using the Bradford reagent. Samples were analyzed on a 
SynaptG2 HDMS mass spectrometer (Waters) equipped with a 
nanoelectrospray source. The instrument was calibrated in resolution mode 
(m/z 1000-7000) using a 100 mg/mL cesium iodide solution prepared in water 
and the quadrupole profile was adjusted to ensure the best transmission in 
the selected mass range. To preserve the integrity of noncovalent complexes 
in the gas phase, the instrument settings were carefully adjusted to the 
following values: capillary voltage, 1.5 kV; sampling cone, 80 V; extraction 
cone, 0 V; backing pressure, 5.2 millibars; cone gas, 20 L/h; source 
temperature, 35°C. Spectra were acquired in positive mode for 5 to 10 
minutes to obtain a good signal-to-noise ratio and processed with MassLynx 
4.1 software (Waters) with minimal smoothing. During in source fragmentation 
experiments the sampling cone voltage was increased up to 130 V. For 
MS/MS analysis of the ligand, the complex was first dissociated in the source 
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and the ligand selected for MS/MS analysis in the quadrupole. MS/MS was 
performed in the Trap region of the instrument using Argon as collision gas 
and a collision energy between 4V and 45V. 
 
SDS poly-acrilamide gel electrophoresis (SDS PAGE) 
Proteins were denatured for 5 min at 99 °C in SDS-PAGE sample buffer 
containing 2% (w/v) SDS and 50 mM dithiothreitol (DTT) (Sigma). Proteins 
were loaded onto 4-12% (w/v) acrylamide gels (BioRad, Hercules, USA). Gels 
were run in 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (BioRad) 
and stained with colloidal Coomassie Blue G-250 (BioRad). 
 
 
In-gel protein digestion and MALDI-ToF analysis 
Stained bands were excised from the gels, washed with 50 mM ammonium 
bicarbonate (Fluka) / acetonitrile (J.T. Baker) 50/50 (vol/vol), washed once 
with pure acetonitrile and air dried. Dried spots were digested for 8 hours at 
37°C in 12 l of 0.012 g/l sequencing grade modified trypsin (Promega, 
Madison, USA), in 5 mM ammonium bicarbonate. After digestion, 0.6 l were 
loaded on a matrix PAC target (Prespotted Anchorchip 96, set for Proteomics, 
Bruker Daltonics, Bremen, Germany) and air-dried. Spots were washed with 
0.6 l of a solution of 70% ethanol (J.T. Baker), 0.1% trifluoroacetic acid 
(Sigma). Mass spectra were acquired on an Ultraflex MALDI ToF-ToF mass 
spectrometer (Bruker Daltonics) in reflectron, positive and negative mode, in 
the mass range of 500 to 3500 m/z. Ions generated by laser desorption at 337 
nm (N2 laser) were recorded with an acceleration voltage of 25 kV in the 
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reflector mode. In general, about 200 single spectra were accumulated for 
improving the signal/noise ration and analyzed by FlexAnalysis (version 2.4, 
Bruker Daltonics). Monoisotopic peaks were annotated with FlexAnalysis 
default parameters and manually revised. Protein identification was carried 
from the generated peaklist using the Mascot program (Mascot server version 
2.2.01, Matrix Science). Mascot was run on a MenB database containing 
protein sequences deduced from the sequenced Neisseria maeningitidis 
serogroup B genomes, downloaded from NCBInr. Search parameters were: 
variable modifications= Oxidation of methionine, cleavage by Trypsin (cleaves 
the C-term side of KR unless next residue is P), mass tolerance= 150 ppm, 
missed cleavage= 1, mass values= M+H+ monoisotopic. Known contaminant 
masses (trypsin, m/z= 842.5094, 1045.5637, 1165.5853, 1179.6010, 
1300.5302, 1713.8084, 1716.8517, 1774.8975, 1993.9767, 2083.0096, 
2211.1040, 2283.1802, 2825.4056) were excluded. Identifications were 
validated when the Mowse score was significant according to Mascot. If 
peptides matched to multiple of a protein family here is reported the protein 
identified as first hit (top rank) by Mascot. 
For the SAL1486 protein and single domains D1, D2, D3 and D4, the stained 
bands were excised from gel, destained and in-gel digested in 5 mM 
ammonium bicarbonate with 12 µg/ml of modified Lys-C protease (Roche, 
Basel, Switzerland) overnight at 37 °C. Guanidination of the C-term lysine 
residues was performed using the ProteoMass Guanidination Kit (Sigma) 
following manifacturer‟s instructions. Modified and unmodified peptide 
solutions were directly spotted to a Prespotted AnchorChip MALDI target 
(Bruker Daltonics) and treated as previously described. 
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Opsonophagocytosis assay 
The opsonophagocytosis assay was performed using GBS strains as target 
cells and HL-60 cell line (ATCC; CCL-240), differentiated into granulocyte-like 
cells, by adding 100 mM N, N dimethylformamide (Sigma) to the growth 
medium for 4 d. Midexponential bacterial cells were incubated at 37°C for 1 h 
in the presence of phagocytic cells, 10% baby rabbit complement (Cedarlane 
Labs, Burlington, Ontario, Canada), and heat-inactivated mouse antisera. 
Negative controls consisted of reactions either with preimmune sera, or 
without HL-60, or with heat-inactivated complement. The amount of 
opsonophagocytic killing was determined by subtracting the log of the number 
of colonies surviving the 1-h assay from the log of the number of CFU at the 
zero time point. 
 
HDX analysis 
The labeling was initiated by dilution of the proteins with 10-fold PBS 1x (pD 
7.0) in 99.9% D2O (Sigma). All exchange reactions were performed on ice. 
Over the time course of the experiment (spanning from 30 sec to 8.5 h), 15 L 
of deuterated samples (55 pmoles) were removed and quenched with 35 L 
of an ice-cold 200 mM Sodium Phosphate solution (pH 2.4) to lower the pH. 
The quenched samples were immediately frozen in dry ice and stored at -
80°C for less than 24 h. Labeled samples were thawed rapidly to 0°C and 
injected into a Shimadzu LC-20ADXR Prominence HPLC system controlled 
by a CMB-20A module. The injector, switching valve, columns, solvents and 
all associated tubings were placed on ice to limit back-exchange. Protein 
samples were trapped and desalted for 2 min at a flow rate of 220 L/min 
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using a Protein Micro Trap column (Michrom BioResources, Inc.) equilibrated 
with 100% buffer A (0.1% formic acid in water). The 2 min desalting step 
allows deuteriums located at fast exchanging sites (i.e. side chains and 
amino/carboxy terminus) to be replaced with hydrogens. Proteins were 
directly eluted into the mass spectrometer at a flow rate of 60 L/min with 
55% solvent B (acetonitrile/water (9/1), 0.1% formic acid). Mass spectra were 
acquired on a Waters SynaptG2 mass spectrometer equipped with a standard 
ESI source using the instrument settings previously reported. Mass spectra 
were acquired in resolution mode (m/z 100-2000) and the calibration was 
performed in positive mode using a 2 mg/mL cesium iodide solution prepared 
in 50% isopropanol. 
 
Bacterial strains and growth conditions 
N. meningitidis MC58 Dgna33 mutant strain was grown in 200 mL GC culture 
medium (BD Biosciences, San Jose, CA, USA) in a humidified atmosphere 
containing 5% CO2 until OD600 0.6. Bacteria were collected by 10 min 
centrifugation at 3500 x g. 
 
Carbonate Extraction 
Bacteria were washed twice with PBS 1x and collected by 10 min 
centrifugation at 3500 x g. Cells were resuspended in 10 ml of PBS 1x and 
sonicated on ice. Any unbroken cells were discarded by centrifugation at 3500 
x g for 10 min and the supernatant was retained for carbonate extraction. The 
supernatant was diluted 10 times with ice-cold 100 mM Sodium Carbonate 
solution (Sigma), pH 11 and slowly stirred for 1 h in an ice bath. The cell 
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membranes are collected by ultracentrifugation of the carbonate extraction 
solution (Beckman Coulter Inc., Brea, CA, USA). The supernatant was 
discarded and the membrane pellet was resuspended in 1 mL PBS 1x. The 
membrane fraction was finally collected by ultracentrifugation at 115000 x g 
for 20 min at 4°C, resuspended with PBS 1x and stored at -20°C. 
 
OMVs preparation 
The culture media recovered after the growth was filtered through a 0.22 mm 
pore size filter (Millipore, Bedford, MA, USA). The filtrates were subjected to 
ultracentrifugation (200000 x g, 180 min). The pellets constituting the m-
OMVs were then resuspended with PBS and stored at -20°C. 
 
In-solution digestion and Nano-LC/MS/MS analysis 
The samples were denatured and reduced with Rapigest® (Waters) and 5 
mm DTT at 100 °C, respectively, for 10 min. The pH was then adjusted to 8.0 
using Ammonium Bicarbonate, and digested overnight with 2 μg of trypsin 
(Promega) at 37°C. The digestion reaction was stopped with formic acid at 
0.1% final concentration. The peptide mixtures were then desalted using 
OASIS cartridges (Waters) following the manufacturer's protocol. Part of the 
digested sample was separated on 500 l of SP Sepharose Fast Flow SCX 
resin (GE Healthcare, UK Limited) following manifacturer‟s instructions, and 
desalted using OASIS cartridges (Waters). Desalted peptides were 
concentrated with a Centrivap Concentrator (Labconco, Kansas City, KS) and 
kept at −20 °C until further analysis. Peptides were separated by nano-LC on 
a NanoAcquity UPLC system (Waters) connected to a Q-ToF Premier ESI 
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mass spectrometer equipped with a nanospray source (Waters). Samples 
were loaded onto a NanoAcquity 1.7-μm BEH130 C18 column (75 μm × 25 
mm; Waters) through a NanoAcquity 5-μm Symmetry® C18 trap column (180 
μm × 20 mm; Waters). Peptides were eluted with a 120-min gradient of 2–
40% of solvent B (98% acetonitrile, 0.1% formic acid) at a flow rate of 250 
nl/min. The eluted peptides were subjected to an automated data-dependent 
acquisition using the MassLynx software, version 4.1 (Waters) where an MS 
survey scan was used to automatically select multicharged peptides over the 
m/z ratio range of 300–2,000 for further MS/MS fragmentation. Up to eight 
different peptides were individually subjected to MS/MS fragmentation 
following each MS survey scan. After data acquisition, individual MS/MS 
spectra were combined, smoothed, and centroided using ProteinLynx, version 
3.5 (Waters) to obtain the peak list file. Protein identification was carried from 
the generated peaklist using the Mascot program (Mascot server version 
2.2.01, Matrix Science). Mascot was run on a MenB database containing 
protein sequences deduced from the sequenced Neisseria maeningitidis 
serogroup B genomes, downloaded from NCBInr. Search parameters were: 
variable modifications= methionine oxidation and glutamine and asparagine 
deamidation, cleavage by Trypsin (cleaves the C-term side of KR unless next 
residue is P), peptide mass tolerance= 0.3 Da, peptide MS/MS tolerance= 0.3 
Da, missed cleavage= 2, mass values= M+H+, M+2H+ and M+3H+. Only 
significant hits were considered as defined by the Mascot scoring and 
probability system. A computational analysis of each identified protein 
sequence was performed with the PSORTb version 2.0 to predict the 
subcellular localization. For PTMs discovery the unidentified spectra, after 
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MASCOT analysis, were manually interpreted searchig for neutral losses or 
reporter ions. 
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